Waldemar Priebe, Ph.D.

Peer-Reviewed Articles

1. Soltyka-Krajewska M, Ziemniak M, Zawadzka-Kazimierczuk A, Skrzypczyk P, Siwiak-Niedbalska E, Jaskiewicz A, Zielinski R, Fokt I, Skora S, Kozminski W, Wozniak K, Priebe W, Pajak-Tarnacka B. Potent Biological Activity of Fluorinated Derivatives of 2-Deoxy-d-Glucose in a Glioblastoma Model. Biomedicines 12(10), 2024. e-Pub 2024. PMID: 39457553.
2. Najem H, Lea ST, Tripathi S, Hurley L, Chen CH, William I, Sooreshjani M, Bowie M, Hartley G, Dussold C, Pacheco S, Dmello C, Lee-Chang C, McCortney K, Steffens A, Walshon J, Ott M, Wei J, Marisetty A, Balyasnikova I, Stupp R, Lukas RV, Hu J, James CD, Horbinski CM, Lesniak MS, Ashley DM, Priebe W, Platanias LC, Curran MA, Heimberger AB. STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma. J Clin Invest 134(12), 2024. e-Pub 2024. PMID: 38941297.
3. Świderski, G, Gołębiewska, E, Kowalczyk, N, Kalinowska, M, Świsłocka, R, Wołejko, E, Wydro, U, Malinowski, P, Pietryczuk, A, Cudowski, A, Priebe, W, Lewandowski, W. Structure, Antioxidant Activity and Antimicrobial Study of Light Lanthanide Complexes with p-Coumaric Acid. Materials 17(6), 2024. e-Pub 2024. PMID: 38541478.
4. Świderski, G, Gołębiewska, E, Kowalczyk, N, Kalinowska, M, Świsłocka, R, Wołejko, E, Wydro, U, Malinowski, P, Pietryczuk, A, Cudowski, A, Priebe, W, Lewandowski, W. Structure, Antioxidant Activity and Antimicrobial Study of Light Lanthanide Complexes with p-Coumaric Acid. Materials 17(6), 2024. e-Pub 2024. PMID: 38541478.
5. Fokt I, Cybulski M, Skora S, Pajak B, Ziemniak M, Wozniak K, Zielinski R, Priebe W. d-Glucose- and d-mannose-based antimetabolites. Part 4: Facile synthesis of mono- and di-acetates of 2-deoxy-d-glucose prodrugs as potentially useful antimetabolites. Carbohydr Res 531:108861, 2023. e-Pub 2023. PMID: 37356236.
6. Guarnieri JW, Dybas JM, Fazelinia H, Kim MS, Frere J, Zhang Y, Soto Albrecht Y, Murdock DG, Angelin A, Singh LN, Weiss SL, Best SM, Lott MT, Zhang S, Cope H, Zaksas V, Saravia-Butler A, Meydan C, Foox J, Mozsary C, Bram Y, Kidane Y, Priebe W, Emmett MR, Meller R, Demharter S, Stentoft-Hansen V, Salvatore M, Galeano D, Enguita FJ, Grabham P, Trovao NS, Singh U, Haltom J, Heise MT, Moorman NJ, Baxter VK, Madden EA, Taft-Benz SA, Anderson EJ, Sanders WA, Dickmander RJ, Baylin SB, Wurtele ES, Moraes-Vieira PM, Taylor D, Mason CE, Schisler JC, Schwartz RE, Beheshti A, Wallace DC. Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts. Sci Transl Med 15(708):eabq1533, 2023. e-Pub 2023. PMID: 37556555.
7. Kalinski P, Kokolus KM, Azrak R, Berezin MY, Brentjens R, Czerniecki B, Dubrov S, Eaton K, Hyland A, Kisailus A, Kortylewski M, Koski GK, Kotula L, Gandhi S, Griffiths EA, Lugowska I, Matosevic S, McAleer C, Mikula M, Nishimura MI, Noyes K, Orabina T, Ozretic P, Paragh G, Parascandola M, Pasukoniene V, Perl A, Powell DJ Jr, Priebe W, Repasky EA, Rudnicki M, Singh AK, Sarnowska E, Suziedelis K, Titkova A, Utz K, Wei WZ, Rutkowski P. MEETING HIGHLIGHTS: THE THIRD MARIE SKLODOWSKA-CURIE SYMPOSIUM ON CANCER RESEARCH AND CARE AT ROSWELL PARK COMPREHENSIVE CANCER CENTER, BUFFALO, NY, SEPTEMBER 20-22, 2023. Wiad Lek 76(12):2543-2555, 2023. e-Pub 2023. PMID: 38290016.
8. Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol 11(2):CNS87, 2022. e-Pub 2022. PMID: 35575067.
9. Ziemniak M, Pawledzio S, Zawadzka-Kazimierczuk A, Dominiak PM, Trzybinski D, Kozminski W, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. Correction: X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution. RSC Adv 12(17):10306, 2022. e-Pub 2022. PMID: 35427095.
10. Ziemniak M, Pawledzio S, Zawadzka-Kazmierczuk A, Dominiak PM, Trzybinski D, Kozminski W, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-d-glucose in solid state and solution. RSC Adv 12(14):8345-8360, 2022. e-Pub 2022. PMID: 35424802.
11. Guarnieri JW, Dybas JM, Fazelinia H, Kim MS, Frere J, Zhang Y, Albrecht YS, Murdock DG, Angelin A, Singh LN, Weiss SL, Best SM, Lott MT, Cope H, Zaksas V, Saravia-Butler A, Meydan C, Foox J, Mozsary C, Kidane YH, Priebe W, Emmett MR, Meller R, Singh U, Bram Y, tenOever BR, Heise MT, Moorman NJ, Madden EA, Taft-Benz SA, Anderson EJ, Sanders WA, Dickmander RJ, Baxter VK, Baylin SB, Wurtele ES, Moraes-Vieira PM, Taylor D, Mason CE, Schisler JC, Schwartz RE, Beheshti A, Wallace DC. Targeted Down Regulation Of Core Mitochondrial Genes During SARS-CoV-2 Infection. bioRxiv, 2022. e-Pub 2022. PMID: 35233572.
12. Pajak B, Siwiak-Niedbalska E, Jaskiewicz A, Soltyka M, Zielinski R, Domoradzki T, Fokt I, Skóra S, Priebe W. Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model. Biomedicines 9(12), 2021. e-Pub 2021. PMID: 34944565.
13. McDonald JT, Enguita FJ, Taylor D, Griffin RJ, Priebe W, Emmett MR, Sajadi MM, Harris AD, Clement J, Dybas JM, Aykin-Burns N, Guarnieri JW, Singh LN, Grabham P, Baylin SB, Yousey A, Pearson AN, Corry PM, Saravia-Butler A, Aunins TR, Sharma S, Nagpal P, Meydan C, Foox J, Mozsary C, Cerqueira B, Zaksas V, Singh U, Wurtele ES, Costes SV, Davanzo GG, Galeano D, Paccanaro A, Meinig SL, Hagan RS, Bowman NM, Consortium UNC, Wolfgang MC, Altinok S, Sapoval N, Treangen TJ, Moraes-Vieira PM, Vanderburg C, Wallace DC, Schisler JC, Mason CE, Chatterjee A, Meller R, Beheshti A. Role of miR-2392 in driving SARS-CoV-2 infection. Cell Rep 37(3):109839, 2021. e-Pub 2021. PMID: 34624208.
14. Kalinowska M, Golebiewska E, Swiderski G, Meczynska-Wielgosz S, Lewandowska H, Pietryczuk A, Cudowski A, Astel A, Swislocka R, Samsonowicz M, Zlowodzka AB, Priebe W, Lewandowski W. Plant-Derived and Dietary Hydroxybenzoic Acids-A Comprehensive Study of Structural, Anti-/Pro-Oxidant, Lipophilic, Antimicrobial, and Cytotoxic Activity in MDA-MB-231 and MCF-7 Cell Lines. Nutrients 13(9), 2021. e-Pub 2021. PMID: 34578985.
15. McDonald JT, Enguita FJ, Taylor D, Griffin RJ, Priebe W, Emmett MR, Sajadi MM, Harris AD, Clement J, Dybas JM, Aykin-Burns N, Guarnieri JW, Singh LN, Grabham P, Baylin SB, Yousey A, Pearson AN, Corry PM, Saravia-Butler A, Aunins TR, Sharma S, Nagpal P, Meydan C, Foox J, Mozsary C, Cerqueira B, Zaksas V, Singh U, Wurtele ES, Costes SV, Davanzo GG, Galeano D, Paccanaro A, Meinig SL, Hagan RS, Bowman NM, Consortium UNC, Wolfgang MC, Altinok S, Sapoval N, Treangen TJ, Moraes-Vieira PM, Vanderburg C, Wallace DC, Schisler J, Mason CE, Chatterjee A, Meller R, Beheshti A. The Great Deceiver: miR-2392's Hidden Role in Driving SARS-CoV-2 Infection. bioRxiv, 2021. e-Pub 2021. PMID: 33948587.
16. Ziemniak M, Zawadzka-Kazimierczuk A, Pawledzio S, Malinska M, Soltyka M, Trzybinski D, Kozminski W, Skora S, Zielinski R, Fokt I, Priebe W, Wozniak K, Pajak B. Experimental and Computational Studies on Structure and Energetic Properties of Halogen Derivatives of 2-Deoxy-D-Glucose. Int J Mol Sci 22(7), 2021. e-Pub 2021. PMID: 33918425.
17. Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab 3(1):122, 2021. e-Pub 2021. PMID: 33340032.
18. Silberman S, Hsu S Muczyczenko Z, Picker D, Sipowicz M, Zak E, Buczynska A, Olejniczak M Priebe W. Design and initiation of pivotal studies for Berubicin, a novel potent topoisomerase II poison for the treatment of recurrent glioblastoma multiforme (GBM). Neuro-Oncol 23:193, 2021. e-Pub 2021.
19. Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab 2(12):1413-1426, 2020. e-Pub 2020. PMID: 33230295.
20. Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy. Clin Cancer Res 26(18):4983-4994, 2020. e-Pub 2020. PMID: 32605912.
21. Sharma P, Roberts C, Herpai D, Fokt ID, Priebe W, Debinski W. Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel) 13(4), 2020. e-Pub 2020. PMID: 32340173.
22. Rios Perez MV, Roife D, Dai B, Pratt M, Dobrowolski R, Kang Y, Li X, Augustine JJ, Zielinski R, Priebe W, Fleming JB. Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models. Surg Open Sci 1(2):Pages 56-63, 2019. e-Pub 2019. PMID: 33981979.
23. Michel KA, Zielinski R, Walker CM, Le Roux L, Priebe W, Bankson JA, Schellingerhout D. Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma. Radiology 293(1):182919, 2019. e-Pub 2019. PMID: 31385757.
24. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. Int J Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
25. Olbryt M, Rusin A, Fokt I, Habryka A, Tudrej P, Student S, Sochanik A, Zielinski R, Priebe W. Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Invest New Drugs 35(5):545-555, 2017. e-Pub 2017. PMID: 28417283.
26. Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W. Novel Molecular Multilevel Targeted Antitumor Agents. Cancer Transl Med 3(3):69-79, 2017. e-Pub 2017. PMID: 28825042.
27. Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, Molina ER, Wu D, Priebe W, Ludwig JA, Mikos AG. MODELING STROMA-INDUCED DRUG RESISTANCE IN A TISSUE-ENGINEERED TUMOR MODEL OF EWING SARCOMA. Tissue Eng Part A 23(1-2):80-89, 2017. e-Pub 2017. PMID: 27923328.
28. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
29. Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med 14(1):46, 2016. e-Pub 2016. PMID: 26861698.
30. Priebe W. Obituary: Derek Horton (1933-2015). Glycoconj J 32(8):557-8, 2015. e-Pub 2015. PMID: 26498188.
31. Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF. Mesenchymal Stem Cells Isolated from Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells 33(8):2400-15, 2015. e-Pub 2015. PMID: 25966666.
32. Malinska M, Fokt I, Priebe W, Wozniak K. Bromine Atom Interactions in Biologically Active Acrylamide Derivatives. Crystal Growth and Design 15(6):2632–2642, 2015. e-Pub 2015.
33. Lee HT, Xue J, Chou PC, Zhou A, Yang P, Conrad CA, Aldape KD, Priebe W, Patterson C, Sawaya R, Xie K, Huang S. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget 6(12):10016-29, 2015. e-Pub 2015. PMID: 25881542.
34. Mansilla S, Vizcaíno C, Rodríguez-Sánchez MA, Priebe W, Portugal J. Autophagy modulates the effects of bis-anthracycline WP631 on p53-deficient prostate cancer cells. J Cell Mol Med 19(4):786-798, 2015. e-Pub 2015. PMID: 25689150.
35. Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger AB. Therapeutic targets in subependymoma. J Neuroimmunol 277(1-2):168-175, 2014. e-Pub 2014. PMID: 25465288.
36. Mielecki M, Milner-Krawczyk M, Grzelak K, Mielecki D, Krzysko KA, Lesyng B, Priebe W. Analogs of Cinnamic Acid Benzyl Amide As Nonclassical Inhibitors of Activated JAK2 Kinase. Curr Cancer Drug Targets. e-Pub 2014. PMID: 25146330.
37. Emmett MR, Kroes RA, Moskal JR, Conrad CA, Priebe W, Laezza F, Meyer-Baese A, Nilsson CL. Integrative Biological Analysis for Neuropsychopharmacology. Neuropsychopharmacology 39(1):5-23, 2014. e-Pub 2014. PMID: 23800968.
38. Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS. Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo. PLoS One 9(5):e95993, 2014. e-Pub 2014. PMID: 24804649.
39. Mielecki M, Krawiec K, Kiburu I, Grzelak K, Zagórski W, Kierdaszuk B, Kowa K, Fokt I, Szymanski S, Swierk P, Szeja W, Priebe W, Lesyng B, LaRonde-LeBlanc N. Development of novel molecular probes of the Rio1 atypical protein kinase. Biochim Biophys Acta 1834(7):1292-301, 2013. e-Pub 2013. PMID: 23523885.
40. Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W. D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose. Carbohydr Res 368:111-9, 2013. e-Pub 2013. PMID: 23376241.
41. Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O. Regulation of HGF expression by ?EGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 15(1):73-84, 2013. e-Pub 2013. PMID: 23359207.
42. Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 14(9):1136-45, 2012. e-Pub 2012. PMID: 22753228.
43. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 30(7):8-17, 2012. e-Pub 2012. PMID: 21792892.
44. Swiatek-Machado K, Mieczkowski J, Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S, Szeja W, Grynkiewicz G, Lesyng B, Priebe W, Kaminska B. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol Ther 13(8):657-70, 2012. e-Pub 2012. PMID: 22555804.
45. Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 107(3):487-501, 2012. e-Pub 2012. PMID: 22249692.
46. Kapuria V, Levitzki A, Bornmann WG, Maxwell D, Priebe W, Sorenson RJ, Showalter HD, Talpaz M, Donato NJ. A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cell Signal 23(12):2076-85, 2011. e-Pub 2011. PMID: 21855629.
47. Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC, Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol 68(4):1033-44, 2011. e-Pub 2011. PMID: 21340606.
48. Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, Eden C, Ellison DW, Priebe W, Koul D, Yung WK, Gajjar A, Stewart CF, Guy RK, Gilbertson RJ. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20(3):384-99, 2011. e-Pub 2011. PMID: 21907928.
49. Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer 117(13):2926-38, 2011. e-Pub 2011. PMID: 21692052.
50. Mansilla S, Priebe W, Portugal J. Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters. Biochim Biophys Acta 1809(7):327-36, 2011. e-Pub 2011. PMID: 21684359.
51. Pastuch G, Wandzik I, Szeja W, Grynkiewicz G, Ramza J, Priebe W, Pucko W. New synthesis of O- and S-glycosyl derivatives of 2-chloro-3-cyano-5-nitropyridine. Heterocyclic Communications 7(4):317-322, 2011. e-Pub 2011.
52. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, Priebe W, Arlinghaus R. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25(3):463-72, 2011. e-Pub 2011. PMID: 21183952.
53. Yan H, Chen X, Zhang Q, Qin J, Li H, Liu C, Calhoun-Davis T, Coletta LD, Klostergaard J, Fokt I, Skora S, Priebe W, Bi Y, Tang DG. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS One 6(9):e24397, 2011. e-Pub 2011. PMID: 21935404.
54. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6(1):e16195, 2011. e-Pub 2011. PMID: 21283755.
55. Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immune therapeutic response. Clin Cancer Res 16(23):5722-33, 2010. e-Pub 2010. PMID: 20921210.
56. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 12(11):1113-25, 2010. e-Pub 2010. PMID: 20667896.
57. Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther 9(7):2026-36, 2010. e-Pub 2010. PMID: 20606045.
58. Kong LY, Gelbard A, Wei J, Reina-Ortiz C, Wang Y, Yang EC, Hailemichael Y, Fokt I, Jayakumar A, Qiao W, Fuller GN, Overwijk WW, Priebe W, Heimberger AB. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res 16(9):2550-61, 2010. e-Pub 2010. PMID: 20388845.
59. He H, Nilsson CL, Emmett MR, Marshall AG, Kroes RA, Moskal JR, Ji Y, Colman H, Priebe W, Lang FF, Conrad CA. Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. J Proteome Res 9(5):2098-108, 2010. e-Pub 2010. PMID: 20199106.
60. Priebe W. Glycals: New Chemistry and Synthesis of Novel Inhibitors of Glycolysis. 17th Annual New Orleans Carbohydrate Symposium, 2010. e-Pub 2010.
61. Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M, Kaboord BJ, Sarracino D, Rezai T, Prakash A, Lopez M, Ji Y, Priebe W, Lang FF, Colman H, Conrad CA. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res 9(1):430-43, 2010. e-Pub 2010. PMID: 19899826.
62. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9(1):67-78, 2010. e-Pub 2010. PMID: 20053772.
63. He H, Nilsson C, Emmett M, Wang X, Marshall A, Kroes R, Moskal J, Ji Y, Priebe W, Colman H, Lang F, Conrad C. Applying FT-ICR MS in a Glycomics Approach Toward Understanding Glioblastoma Cancer Stem Cell Differentiation. Glycobiology 19(11):1365, 2009. e-Pub 2009.
64. Fokt I, Szymanski S, Skora S, Cybulski M, Madden T, Priebe W. D-Glucose- and D-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-D-glucoses and -D-mannoses. Carbohydr Res 344(12):1464-1473, 2009. e-Pub 2009. PMID: 19625015.
65. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58(7):1023-32, 2009. e-Pub 2009. PMID: 19002459.
66. Swiatek-Machado K, Ellert-Miklaszewska A, Szeja W, Priebe W, Grynkiewicz G, Lesyng B, Kaminska B. Evaluation of antitumor activity of novel inhibitors of JAK/STAT3 pathway in glioma cells. FEBS Journal 276(S1):392, 2009. e-Pub 2009.
67. Gao H, Priebe W, Glod J, Banerjee D. Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium. Stem Cells 27(4):857-865, 2009. e-Pub 2009. PMID: 19350687.
68. Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, Zhao M, Ju J, Mandal M, Jasser S, Madden T, Myers JN, Priebe W. Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 8(2):117-27, 2009. e-Pub 2009. PMID: 20192118.
69. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14(24):8228-35, 2008. e-Pub 2008. PMID: 19088040.
70. Korchowiec J, Korchowiec B, Priebe W, Rogalska E. DFT study on the selectivity of complexation of metal cations with a dioxadithia crown ether ligand. J Phys Chem A 112(51):13633-40, 2008. e-Pub 2008. PMID: 19055400.
71. van Schalkwyk DA, Priebe W, Saliba KJ. The inhibitory effect of 2-halo derivatives of D-glucose on glycolysis and on the proliferation of the human malaria parasite Plasmodium falciparum. J Pharmacol Exp Ther 327(2):511-7, 2008. e-Pub 2008. PMID: 18713952.
72. Heimberger AB, Priebe W. Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers. Recent Pat CNS Drug Discov 3(3):179-88, 2008. e-Pub 2008. PMID: 18991807.
73. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14(18):5759-68, 2008. e-Pub 2008. PMID: 18794085.
74. Corvis Y, Korchowiec B, Korchowiec J, Badis M, Mironiuk-Puchalska E, Fokt I, Priebe W, Rogalska E. Complexation of metal ions in Langmuir films formed with two amphiphilic dioxadithia crown ethers. J Phys Chem B 112(35):10953-63, 2008. e-Pub 2008. PMID: 18698707.
75. Bednarek E, Sitkowski J, Kawecki R, Kozerski L, Bocian W, Pazderski L, Priebe W. Structure and dynamics of methyl cis-3,4-diamino-2,3,4,6-tetradeoxy-alpha-l-lyxo-hexopyranoside complexes with PtCl(2) and PdCl(2), by (1)H, (2)H, (13)C, (15)N and (195)Pt NMR spectroscopy in DMSO, CD(3)CN and H(2)O. Dalton Trans N/A(31):4129-37, 2008. e-Pub 2008. PMID: 18688431.
76. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14(3):788-796, 2008. e-Pub 2008. PMID: 18245540.
77. Gruber BM, Anuszewska EL, Bubko I, Kasprzycka-Guttman T, Misiewicz I, Skupinska K, Fokt I, Priebe W. NF kappa B activation and drug sensitivity in human neoplastic cells treated with anthracyclines. Acta Poloniae Pharmaceutica 65(2):267-71, 2008. e-Pub 2008. PMID: 18666436.
78. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67(23):11291-9, 2007. e-Pub 2007. PMID: 18056455.
79. Tamura A, Onishi Y, An R, Koshiba S, Wakabayashi K, Hoshijima K, Priebe W, Yoshida T, Kometani S, Matsubara T, Mikuriya K, Ishikawa T. In Vitro Evaluation of Photosensitivity Risk related to Genetic Polymorphisms of Human ABC Transporter ABCG2 and Inhibition by Drugs. Drug Metab Pharmacokinet 22(6):428-440, 2007. e-Pub 2007. PMID: 18159130.
80. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67(20):9630-6, 2007. e-Pub 2007. PMID: 17942891.
81. Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemother Pharmacol 60(5):625-33, 2007. e-Pub 2007. PMID: 17195067.
82. Bidwell GL, Davis AN, Fokt I, Priebe W, Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs 25(4):313-26, 2007. e-Pub 2007. PMID: 17483874.
83. Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Fokt I, Priebe W. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz) 55(3):193-8, 2007. e-Pub 2007. PMID: 17557149.
84. Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109(8):3470-3478, 2007. e-Pub 2007. PMID: 17202319.
85. Mansilla S, Rojas M, Bataller M, Priebe W, Portugal J. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochem Pharmacol 73(7):934-42, 2007. e-Pub 2007. PMID: 17217917.
86. Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest New Drugs 25(2):115-122, 2007. e-Pub 2007. PMID: 17072745.
87. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26(17):2435-2444, 2007. e-Pub 2007. PMID: 17043651.
88. Bidwell GL, Fokt I, Priebe W, Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 73(5):620-31, 2007. e-Pub 2007. PMID: 17161827.
89. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67(2):684-694, 2007. e-Pub 2007. PMID: 17234779.
90. Schroeder C, Fokt I, Johansen M, Rhea R, Allen TL, Madden T, Priebe W. WP760, a new DNA-binding agent with unique melanoma selectivity. Molecular Cancer Therapeutics 6(12):3407S-3407S, 2007. e-Pub 2007.
91. Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V, Szymanski S, Fokt I, Rudnicki WR, Ginalski K, Lesyng B, Priebe W. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol 58(6):725-34, 2006. e-Pub 2006. PMID: 16555088.
92. Mansilla S, Priebe W, Portugal J. Transcriptional changes facilitate mitotic catastrophe in tumor cells that contain functional p53. Eur J Pharmacol 540(1-3):34-45, 2006. e-Pub 2006. PMID: 16735036.
93. Anuszewska E, Chlopkiewicz B, Gruber B, Marczewska J, Priebe W, Skurzak H. Estimation of DNA damage and cytotoxicity of anthracycline analogs in human melanoma cells on early and late passages. Acta Pol Pharm 63(4):321-4, 2006. e-Pub 2006. PMID: 17203872.
94. Gruber BM, Anuszewska EL, Roman I, Gozdzik A, Priebe W, Fokt I. Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells. Acta Pol Pharm 63(1):15-8, 2006. e-Pub 2006. PMID: 17515324.
95. Mansilla S, Priebe W, Portugal J. Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 5(1):53-60, 2006. e-Pub 2006. PMID: 16319532.
96. Portugal J, Cashman DJ, Trent JO, Ferrer-Miralles N, Przewloka T, Fokt I, Priebe W, Chaires JB. A new bisintercalating anthracycline with picomolar DNA binding affinity. J Med Chem 48(26):8209-19, 2005. e-Pub 2005. PMID: 16366602.
97. Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res 25(3B):1841-50, 2005. e-Pub 2005. PMID: 16158916.
98. Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Priebe W, Fokt I. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. Anticancer Res 25(3B):2193-8, 2005. e-Pub 2005. PMID: 16158963.
99. Chlopkiewicz B, Ejchart A, Marczewska J, Anuszewska E, Priebe W. Evaluation of mutagenic and genotoxic activities of new derivatives of anthracyclines. Acta Pol Pharm 62(2):99-104, 2005. e-Pub 2005. PMID: 16161349.
100. Maher JC, Savaraj N, Priebe W, Liu H, Lampidis TJ. Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas 30(2):e34-9, 2005. e-Pub 2005. PMID: 15714127.
101. Gruber BM, Anuszewska EL, Bubko I, Kasprzycka-Guttman T, Misiewicz I, Skupinska K, Priebe W, Fokt I. Constitutive activation of transcription factor NFkappaB as a possible marker of sensitivity of neoplastic cells to anthracyclines. Acta Pol Pharm 62(1):17-23, 2005. e-Pub 2005. PMID: 16022489.
102. Fokt I, Grynkiewicz G, Skibicki P, Przewloka T, Priebe W. New Strategies Towards Synthesis of Doxorubicin Analogs. Polish J. Chem 79:349-359, 2005. e-Pub 2005.
103. Nair RR, Wang H, Jamaluddin MS, Fokt I, Priebe W, Boyd DD. A bisanthracycline (WP631) represses uPAR gene expression and cell migration of RKO colon cancer cells by interfering with transcription factor binding to a chromatin-accessible -148/-124 promoter region. Oncol Res 15(5):265-79, 2005. e-Pub 2005. PMID: 16261846.
104. Frelek J, Kaminska A, Pakulski Z, Szmigielski R, Priebe W. Chirality Probing of Chlorotetrabutyratodiruthenium (II,III) Complexes with vic-Amino Alcohols by Circular Dichroism Spectroscopy. Polish J. Chem 79:387-399, 2005. e-Pub 2005.
105. Grynkiewicz G, Fokt I, Skibicki P, Przewloka T, Szeja W, Priebe W. Synthesis of 1- O-Silylated 3-Azido- and 3-N-Trifluoroacetamido-2,3,6-trideoxy-L-arabino and L-lyxo-hexapyranoses, Convenient Glycosyl Donors for Preparation of Anthracyclic Antibiotics and Related DNA-Binding Agents. Polish J. Chem 79:335-347, 2005. e-Pub 2005.
106. Fanale MA, Liu Y, McKenzie TS, Fokt I, Priebe W. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. Journal of Clinical Oncology 23(16):155S-155S part 1Suppl. S, 2005. e-Pub 2005.
107. Marczewska J, Anuszewska EL, Priebe W. The application of the sister chromatid exchange test for evaluation of the novel anthracycline derivatives. Part I. Acta Pol Pharm 61 Suppl:22-4, 2004. e-Pub 2004. PMID: 15909928.
108. Trevino AV, Woynarowska BA, Herman TS, Priebe W, Woynarowski JM. Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues. Mol Cancer Ther 3(11):1403-10, 2004. e-Pub 2004. PMID: 15542779.
109. Inge TH, Harris NL, Wu J, Azizkhan RG, Priebe W. WP744 is a novel anthracycline with enhanced activity against neuroblastoma. J Surg Res 121(2):187-96, 2004. e-Pub 2004. PMID: 15501458.
110. Fox KR, Webster R, Phelps RJ, Fokt I, Priebe W. Sequence selective binding of bis-daunorubicin WP631 to DNA. Eur J Biochem 271(17):3556-66, 2004. e-Pub 2004. PMID: 15317591.
111. Mansilla S, Priebe W, Portugal J. Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Biochemistry 43(23):7584-92, 2004. e-Pub 2004. PMID: 15182200.
112. Kutsch O, Levy DN, Bates PJ, Decker J, Kosloff BR, Shaw GM, Priebe W, Benveniste EN. Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob Agents Chemother 48(5):1652-63, 2004. e-Pub 2004. PMID: 15105117.
113. Pozarowski P, Huang X, Gong RW, Priebe W, Darzynkiewicz Z. Simple, semiautomatic assay of cytostatic and cytotoxic effects of antitumor drugs by laser scanning cytometry: effects of the bis-intercalator WP631 on growth and cell cycle of T-24 cells. Cytometry A 57(2):113-9, 2004. e-Pub 2004. PMID: 14750133.
114. Ashikawa K, Shishodia S, Fokt I, Priebe W, Aggarwal BB. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem Pharmacol 67(2):353-64, 2004. e-Pub 2004. PMID: 14698047.
115. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64(1):31-4, 2004. e-Pub 2004. PMID: 14729604.
116. Gruber BM, Anuszewska EL, Priebe W. The effect of new anthracycline derivatives on the induction of apoptotic processes in human neoplastic cells. Folia Histochem Cytobiol 42(2):127-30, 2004. e-Pub 2004. PMID: 15253137.
117. Pawlowska J, Priebe W, Paine MJ, Wolf CR, Borowski E, Tarasiuk J. The ability of new sugar-modified derivatives of antitumor anthracycline, daunorubicin, to stimulate NAD(P)H oxidation in different cellular oxidoreductase systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res 14(10):469-74, 2004. e-Pub 2004. PMID: 15559760.
118. Fuks L, Samochocka K, Anulewicz-Ostrowska R, Kruszewski M, Priebe W, Lewandowski W. Structure and biological activity of cationic [PtLCl(DMSO)]NO(3).DMSO complex containing a chelated diaminosugar: methyl-3,4-diamino-2,3,4,6-tetradeoxy-alpha-L-lyxopyranoside. Eur J Med Chem 38(7-8):775-80, 2003. e-Pub 2003. PMID: 12932909.
119. Haj HT, Salerno M, Priebe W, Kozlowski H, Garnier-Suillerot A. New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chem Biol Interact 145(3):349-58, 2003. e-Pub 2003. PMID: 12732461.
120. Villamarín S, Mansilla S, Ferrer-Miralles N, Priebe W, Portugal J. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur J Biochem 270(4):764-70, 2003. e-Pub 2003. PMID: 12581216.
121. Kruszewski M, Bouzyk E, Oldak T, Samochocka K, Fuks L, Lewandowski W, Fokt I, Priebe W. Differential toxic effect of cis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. Teratog Carcinog Mutagen Suppl(1):1-11, 2003. e-Pub 2003. PMID: 12616592.
122. Samochocka K, Fokt I, Anulewicz-Ostrowska R, Przewloka T, Mazurek AP, Fuks L, Lewandowski W, Kozerski L, Bocian W, Bednarek E, Lewandowska H, Sitkowski J Priebe W. Platinum(II) and Palladium(II) Complexes with Methyl 3,4-diamino-2,3,4,6 tetradeoxy-a-L-lyxo-hexopyranoside. Dalton Trans:2177-83, 2003. e-Pub 2003.
123. Liu H, Savaraj N, Priebe W, Lampidis TJ. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol 64(12):1745-51, 2002. e-Pub 2002. PMID: 12445863.
124. Inge TH, Casson LK, Priebe W, Trent JO, Georgeson KE, Miller DM, Bates PJ. Importance of Sp1 consensus motifs in the MYCN promoter. Surgery 132(2):232-8, 2002. e-Pub 2002. PMID: 12219017.
125. Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 50(1):6-8, 2002. e-Pub 2002. PMID: 12111105.
126. Salerno M, Przewloka T, Fokt I, Priebe W, Garnier-Suillerot A. Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. Biochem Pharmacol 63(8):1471-9, 2002. e-Pub 2002. PMID: 11996888.
127. Villamarín S, Ferrer-Miralles N, Mansilla S, Priebe W, Portugal J. Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochem Pharmacol 63(7):1251-8, 2002. e-Pub 2002. PMID: 11960601.
128. Lewandowski, Dasiewicz B, Koczon P, Skierski J, Dobrosz-Teperek K, Swislocka R, Fuks L, Priebe W, Mazurek AP. Vibrational Study of Alkaline Metal Nicotinates Benzoates, and Salicylates. J Mol Struct 604:189-193, 2002. e-Pub 2002.
129. Samochocka, Lewandowski W, Priebe W, Fuks L. Vibrational studies of Pt(II) and Pd(II) complexation by 3,4-diamino-lyxo-L-hexopyranoside. . J Mole Struct 614(1-3):203-9, 2002. e-Pub 2002.
130. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21(6A):3777-84, 2001. e-Pub 2001. PMID: 11911247.
131. Loetchutinat C, Heywang C, Priebe W, Garnier-Suillerot A. The absence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin. Biochem Pharmacol 62(5):561-7, 2001. e-Pub 2001. PMID: 11585053.
132. Loetchutinat C, Priebe W, Garnier-Suillerot A. Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells. Eur J Biochem 268(16):4459-67, 2001. e-Pub 2001. PMID: 11502206.
133. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40(18):5542-7, 2001. e-Pub 2001. PMID: 11331019.
134. Frezard F, Pereira-Maia E, Quidu P, Priebe W, Garnier-Suillerot A. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Eur J Biochem 268(6):1561-7, 2001. e-Pub 2001. PMID: 11248673.
135. Priebe W, Fokt I, Przewloka T, Chaires JB, Portugal J, Trent JO. Exploiting anthracycline scaffold for designing DNA-targeting agents. Methods Enzymol 340:529-55, 2001. e-Pub 2001. PMID: 11494869.
136. Hu Y, Moraes CT, Savaraj N, Priebe W, Lampidis TJ. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochem Pharmacol 60(12):1897-905, 2000. e-Pub 2000. PMID: 11108806.
137. Marbeuf-Gueye C, Priebe W, Garnier-Suillerot A. Multidrug resistance protein functionality: no effect of intracellular or extracellular pH changes. Biochem Pharmacol 60(10):1485-9, 2000. e-Pub 2000. PMID: 11020450.
138. Hooijberg JH, Pinedo HM, Vrasdonk C, Priebe W, Lankelma J, Broxterman HJ. The effect of glutathione on the ATPase activity of MRP1 in its natural membranes. FEBS Lett 469(1):47-51, 2000. e-Pub 2000. PMID: 10708754.
139. Priebe W. Targeting DNA with Anthracyclines: The Importance of the Sugar Moiety. Molecules 5(3):299-301. e-Pub 2000.
140. Qu X, Trent JO, Fokt I, Priebe W, Allosteric CJ, Drug C, DNA PNAS BT. Binding to DNA. [selected for a PNAS commentary: Waring M. Facilitating structural transitions in DNA. PNAS 78: 7-8, 2000; also see Chemical & Engineering News: News of The Week: S. Borman. Left-handed DNA Finally Gets Some Recognition. 78 (42): 7-8, 2000; Scientific American: News in Brief: Left-handed DNA’s left hook? October 20, 2000]. PNAS 97:12032-12037, 2000. e-Pub 2000.
141. Booser DJ, Perez-Soler R, Cossum P, Esparza-Guerra L, Wu QP, Zou Y, Priebe W, Hortobagyi GN. Phase I study of liposomal annamycin. Cancer Chemother Pharmacol 46(5):427-32, 2000. e-Pub 2000. PMID: 11127949.
142. Rudnicki WR, Kurzepa M, Szczepanik T, Priebe W, Lesyng B. A simple model for predicting the free energy of binding between anthracycline antibiotics and DNA. Acta Biochim Pol 47(1):1-9, 2000. e-Pub 2000. PMID: 10961673.
143. Martin B, Vaquero A, Priebe W, Portugal J. Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro. Nucleic Acids Res 27(17):3402-9, 1999. e-Pub 1999. PMID: 10446226.
144. Marbeuf-Gueye C, Ettori D, Priebe W, Kozlowski H, Garnier-Suillerot A. Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. Biochim Biophys Acta 1450(3):374-84, 1999. e-Pub 1999. PMID: 10395948.
145. Priebe W, Skibicki P, Neamati N, Achmatowicz O, Grynkiewicz G, Szechner B. Synthesis of kedarosamine, a sugar portion of the chromoprotein antibiotic kedarcidine. Polish J Chem 73:1143-52, 1999. e-Pub 1999.
146. Priebe W, Booser D, Perez-Soler R. Annamycin, a novel liposomally formulated anticancer agent. Cell. Mol. Biol. Lett 4:247, 1999. e-Pub 1999.
147. Grynkiewicz G, Zagrodzka J, Priebe W. Enantioselective HPLC of chiral intermediates in the total synthesis of 4-demethoxydaunomycinone. J Chromatography 830:191-5, 1999. e-Pub 1999.
148. Tarasiuk J, Tkaczyk-Gobis K, Stefanska B, Dzieduszycka M, Priebe W, Martelli S, Borowski E. The role of structural factors of anthraquinone compounds and their quinone-modified analogues in NADH dehydrogenase-catalysed oxygen radical formation. Anticancer Drug Des 13(8):923-39, 1998. e-Pub 1998. PMID: 10335267.
149. Dutta R, Gao YG, Priebe W, Wang AH. Binding of the modified daunorubicin WP401 adjacent to a T-G base pair induces the reverse Watson-Crick conformation: crystal structures of the WP401-TGGCCG and WP401-CGG[br5C]CG complexes. Nucleic Acids Res 26(12):3001-5, 1998. e-Pub 1998. PMID: 9611247.
150. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 247(3):859-63, 1998. e-Pub 1998. PMID: 9647783.
151. Leng F, Priebe W, Chaires JB. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. Biochemistry 37(7):1743-53, 1998. e-Pub 1998. PMID: 9485299.
152. Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Mol Pharmacol 53(1):141-7, 1998. e-Pub 1998. PMID: 9443942.
153. Robinson H, Priebe W, Chaires JB, Wang AH. Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. Biochemistry 36(29):8663-70, 1997. e-Pub 1997. PMID: 9289011.
154. Hu GG, Shui X, Leng F, Priebe W, Chaires JB, Williams LD. Structure of a DNA-bisdaunomycin complex. Biochemistry 36(20):5940-6, 1997. e-Pub 1997. PMID: 9166763.
155. Perez-Soler R, Neamati N, Zou Y, Schneider E, Doyle LA, Andreeff M, Priebe W, Ling YH. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Int J Cancer 71(1):35-41, 1997. e-Pub 1997. PMID: 9096663.
156. Lampidis TJ, Kolonias D, Podona T, Israel M, Safa AR, Lothstein L, Savaraj N, Tapiero H, Priebe W. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry 36(9):2679-85, 1997. e-Pub 1997. PMID: 9054575.
157. Chaires JB, Leng F, Przewloka T, Fokt I, Ling YH, Perez-Soler R, Priebe W. Structure-based design of a new bisintercalating anthracycline antibiotic. J Med Chem 40(3):261-6, 1997. e-Pub 1997. PMID: 9022792.
158. Yan Q, Priebe W, Chaires JB, Czernuszewicz RS. Interaction of doxorubicin and its derivatives with DNA: Elucidation by Resonance Raman and surface-enhanced Resonance Raman spectroscopy. . Biospectroscopy 3:307-16, 1997. e-Pub 1997.
159. Gallois L, Fiallo M, Laigle A, Priebe W, Garnier-Suillerot A. The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids. Eur J Biochem 241(3):879-87, 1996. e-Pub 1996. PMID: 8944778.
160. Gao YG, Priebe W, Wang AH. Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity. Eur J Biochem 240(2):331-5, 1996. e-Pub 1996. PMID: 8841395.
161. Consoli U, Priebe W, Ling YH, Mahadevia R, Griffin M, Zhao S, Perez-Soler R, Andreeff M. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 88(2):633-44, 1996. e-Pub 1996. PMID: 8695811.
162. Lewandowski W, Priebe W, Koczon P, Moscibroda P, Orzechowska A. The influence of selected metals and halogens on the electronic system of benzoic acid. Anal Bioanal Chem 355(5-6):750-2, 1996. e-Pub 1996. PMID: 15045363.
163. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49(5):832-41, 1996. e-Pub 1996. PMID: 8622633.
164. Jolles B, Laigle A, Priebe W, Garnier-Suillerot A. Comparison of DNA sequence selectivity of anthracycline antibiotics and their 3'-hydroxylated analogs. Chem Biol Interact 100(2):165-76, 1996. e-Pub 1996. PMID: 8646789.
165. Chaires JB, Satyanarayana S, Suh D, Fokt I, Przewloka T, Priebe W. Parsing the free energy of anthracycline antibiotic binding to DNA. Biochemistry 35(7):2047-53, 1996. e-Pub 1996. PMID: 8652545.
166. Przybysz B, Szeja W, Grynkiewicz G, Priebe W. A facile transformation of benzylated methyl glycosides into thioglycosides. Polish J Chem 70:1270, 1996. e-Pub 1996.
167. Leng F, Savkur R, Fokt I, Przewloka T, Priebe W, Chaires JB. Base Specific and regioselective chemical cross-linking of daunorubicin to DNA. J Am Chem Soc 118:4731-8, 1996. e-Pub 1996.
168. Koczon P, Lewandowski W, Moscibroda P, Priebe W, Wieckowska E. The comparison of the influence of ionic potential and electronegativity of selected metals and halogens on the electronic system of benzoic acid. Cancer J Appl Spectr 41:144-9, 1996. e-Pub 1996.
169. Zou Y, Priebe W, Perez-Soler R. Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size. Cancer Chemother Pharmacol 39(1-2):103-8, 1996. e-Pub 1996. PMID: 8995506.
170. Ishikawa T, Akimaru K, Kuo MT, Priebe W, Suzuki M. How does the MRP/GS-X pump export doxorubicin?. J Natl Cancer Inst 87(21):1639-40, 1995. e-Pub 1995. PMID: 7563208.
171. Zou Y, Priebe W, Stephens LC, Perez-Soler R. Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. Clin Cancer Res 1(11):1369-74, 1995. e-Pub 1995. PMID: 9815933.
172. Ling YH, Zou Y, Priebe W, Perez-Soler R. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. Int J Cancer 61(3):402-8, 1995. e-Pub 1995. PMID: 7729954.
173. Zou Y, Ling YH, Reddy S, Priebe W, Perez-Soler R. Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. Int J Cancer 61(5):666-71, 1995. e-Pub 1995. PMID: 7768640.
174. Lothstein L, Sweatman TW, Priebe W. Hydroxylation at C-3’ of doxorubicin alters the selected phenotype of cellular drug resistance. Bioorgan Med Chem Lett 5:1807-12, 1995. e-Pub 1995.
175. Priebe W. Mechanism of action-governed design of anthracycline antibiotics: A turn off/turn-on approach. Current Pharmaceutical Design 1:51-68, 1995. e-Pub 1995.
176. Borrel MN, Fiallo M, Priebe W, Garnier-Suillerot A. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. FEBS Lett 356(2-3):287-99, 1994. e-Pub 1994. PMID: 7805856.
177. Zhao JY, Savaraj N, Song R, Priebe W, Kuo MT. Overexpression of P-glycoprotein but not its mRNA in multidrug resistant cells selected with hydroxyrubicin. Anticancer Res 14(5A):1735-42, 1994. e-Pub 1994. PMID: 7531410.
178. Solary E, Ling YH, Perez-Soler R, Priebe W, Pommier Y. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. Int J Cancer 58(1):85-94, 1994. e-Pub 1994. PMID: 8014019.
179. Zou Y, Ling YH, Van NT, Priebe W, Perez-Soler R. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 54(6):1479-84, 1994. e-Pub 1994. PMID: 8137251.
180. Perez-Soler R, Zou Y, Y-H L, Priebe W. The use of liposomes as carriers of lipophilic anthracycline antibiotics. J Liposome Res 4:555-73, 1994. e-Pub 1994.
181. Perez-Soler R, Ling YH, Zou Y, Priebe W. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. Cancer Chemother Pharmacol 34(2):109-18, 1994. e-Pub 1994. PMID: 8194162.
182. Ostrowski S, Burke T, Priebe, WC. NMR Spectra of allosteric effectors of human hemoglobine. Magn Res Chem 32:182-3, 1994. e-Pub 1994.
183. Zou Y, Hayman A, Priebe W, Perez-Soler R. Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography. J Pharm Sci 82(11):1151-4, 1993. e-Pub 1993. PMID: 8289131.
184. Horton D, Priebe W, Sznaidman ML, Varela O. Synthesis and antitumor activity of anthracycline disaccharide glycosides containing daunosamine. J Antibiot (Tokyo) 46(11):1720-30, 1993. e-Pub 1993. PMID: 8270495.
185. Horton D, Issa M, Priebe W, Sznaidman ML. Synthesis of 3-deoxyaldulosonic acid esters by one-carbon chain extension of glycal-derived lactone precursors. Carbohydr Res 246:105-18, 1993. e-Pub 1993. PMID: 8370034.
186. Ling YH, Priebe W, Yang LY, Burke TG, Pommier Y, Perez-Soler R. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res 53(7):1583-9, 1993. e-Pub 1993. PMID: 8453627.
187. Ling YH, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells. Cancer Res 53(8):1845-52, 1993. e-Pub 1993. PMID: 8467504.
188. Priebe W, Van NT, Burke TG, Perez-Soler R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs 4(1):37-48, 1993. e-Pub 1993. PMID: 8457713.
189. Y-H L, Priebe W, Perez-Soler R. Intrinsic cytotoxicity and reversal of multidrug resistance by monensin in KB parent and MDR cells. Int J Oncol 3:971-7, 1993. e-Pub 1993.
190. Horton D, Priebe W, Sznaidman ML. Steric and conformational effects in the dehalogenation of 2-halo sugar derivatives with tributylstannane. J Org Chem 58:1821-6, 1993. e-Pub 1993.
191. Chaires JB, Priebe W, Graves DE, Burke TG. Dissection of the free energy of anthracycline antibiotic binding to DNA: electrostatic contributions. J Am Chem Soc 115:5360-4, 1993. e-Pub 1993.
192. Zou Y, Priebe W, Ling YH, Perez-Soler R. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemother Pharmacol 32(3):190-6, 1993. e-Pub 1993. PMID: 8500223.
193. Lothstein L, Hosey LM, Sweatman TW, Koseki Y, Dockter M, Priebe W. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance. Oncol Res 5(6-7):229-34, 1993. e-Pub 1993. PMID: 7907237.
194. Priebe W, Neamati N, Perez-Soler R. 3'-Hydroxyesorubicin halogenated at C-2'. J Antibiot (Tokyo) 45:386-93, 1992. e-Pub 1992. PMID: 1577666.
195. Perez-Soler R, Priebe W. Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin. Cancer Chemother Pharmacol 30(4):267-71, 1992. e-Pub 1992. PMID: 1643693.
196. Priebe, Grynkiewicz G, of glycals NNOSC, at C- -H. One step C-acylation of glycals and 2-deoxy hexopyranoses at C-2. Tetrahedron Lett 33:7681-4, 1992. e-Pub 1992.
197. Priebe W, Grynkiewicz, G, Neamati N, Perez-Soler R. A facile method for preparation of 3-thio-sugars and 3-thio-glycals. Synthesis of 3'-mercapto-3'-deamino-doxorubicin. Tetrahedron Lett 32:3313-6, 1991. e-Pub 1991.
198. Priebe W, Grynkiewicz G, Neamati N. 2-Deoxy-1-O-silylated-b-hexopyranoses. Useful glycosyl donors synthetic intermediates. Tetrahedron Lett 32:2079-82, 1991. e-Pub 1991.
199. Priebe W, Grynkiewicz G. A facile and selective oxidation of sulfides to sulfones. Tetrahedron Lett 32:7353-6, 1991. e-Pub 1991.
200. Priebe W, Grynkiewicz G, Neamati N. Synthesis of new 1-C-(2-furyl)- and 3-C-(2-furyl) hexopyranosides and 3-C-(2-furyl)daunorubicin analogs. Monatshefte fur Chemie 22:419, 1991. e-Pub 1991.
201. Priebe W, Neamati N, Perez-Soler R. 3'-Hydroxyesorubicin. Synthesis and antitumor activity. J Antibiot (Tokyo) 43(7):838-46, 1990. e-Pub 1990. PMID: 2387778.
202. Perez-Soler R, Priebe W. Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. Cancer Res 50(14):4260-6, 1990. e-Pub 1990. PMID: 2194651.
203. Horton D, Priebe W, Carter JP, Filppi J, Wolgemuth RL. 4-Demethoxy-3'-N-trifluoroacetyldoxorubicin. Synthesis and solid tumor activity. Drug Des Deliv 6(2):123-9, 1990. e-Pub 1990. PMID: 2080980.
204. Priebe W, Horton D, Sznaidman M. Iodoalkoxylation of 1.5-anhydro-2-deoxy-hex-1enitols (glycals). Carbohyd Res 205:71-86, 1990. e-Pub 1990.
205. Horton D, Priebe W, Sznaidman M. A new approach to 2-deoxyglycosides permitting access to anthracycline glycosides specifically labeled at the 2'-position. Carbohydr Res 187(1):149-53, 1989. e-Pub 1989. PMID: 2752389.
206. Horton D, Priebe W, Sznaidman M. Preparation of 4-O-acetyl-1,5-anhydro-2,3,6-trideoxy-3-trifluoroacetamido-L- lyxo-hex-1-enitol, a key intermediate in synthesis of daunosamine glycosides. Carbohydr Res 187(1):145-8, 1989. e-Pub 1989. PMID: 2752388.
207. Horton D, Priebe W, Sznaidman M. Preparative procedures for conversion of daunorubicin into doxorubicin (Adriamycin) and 14-O-acetyldoxorubicin by way of 14-bromodaunorubicin. Carbohydr Res 184:231-5, 1988. e-Pub 1988. PMID: 3242811.
208. Chmielewski M, Jurczak J, Priebe W, Horton D. Reverse anomeric effect of the carbamoyl group of 2,6-disubstituted-6-carbamoyl-5,6-dihydro-2H- pyrans. Magn. Res Chem 25:161-5, 1987. e-Pub 1987.
209. Horton D, Priebe W, Varela O. Halogenation of 1,5-anhydrohex-1-enitols influence of the C-6 substituent. J Org Chem 51:3479-85, 1986. e-Pub 1986.
210. Horton D, Priebe W, Varela O. Synthesis and antitumor activity of 2'-bromo- and 2'-chloro-3'-acetoxy-3'-deaminodaunorubicin analogs. Carbohydr Res 144(2):305-15, 1985. e-Pub 1985. PMID: 4092209.
211. Horton D, Priebe W, Varela O. Selective silylation of 6-deoxyglycals. Carbohydr Res 144(2):325-30, 1985. e-Pub 1985. PMID: 4092211.
212. Bhate P, Horton D, Priebe W. Allylic rearrangement of 6-deoxyglycals having practical utility. Carbohydr Res 144(2):331-7, 1985. e-Pub 1985. PMID: 4092212.
213. Cheung TM, Horton D, Priebe W, Turner WR, Weckerle W. Sugar-ring analogs of daunorubicin: 3'-epidaunorubicin, 3'-hydroxy-3',5'-diepidaunorubicin and 3',6'-dihydroxy-3',5'-diepidaunorubicin. J Antibiot (Tokyo) 38(5):683-6, 1985. e-Pub 1985. PMID: 4019314.
214. Horton D, Priebe W. Oxyhalogenation of glycals for the synthesis of anti-tumor-active 2'-halo daunorubicin analogs. Carbohydr Res 136:391-6, 1985. e-Pub 1985. PMID: 4005892.
215. Horton D, Priebe W, Varela O. Selective acylation of 6-deoxyglycals. Carbohyd Res 144:317-42, 1985. e-Pub 1985.
216. Horton D, Priebe W, Varela O. 3'-Deamino-4'-epi-3'-hydroxy-daunorubicin and -doxorubicin. Synthesis and antitumor activity. J Antibiot (Tokyo) 37(12):1635-41, 1984. e-Pub 1984. PMID: 6549317.
217. Horton D, Priebe W, Varela O. Synthesis and antitumor activity of 3'-deamino-3'-hydroxydoxorubicin. A facile procedure for the preparation of doxorubicin analogs. J Antibiot (Tokyo) 37(8):853-8, 1984. e-Pub 1984. PMID: 6548219.
218. Horton D, Priebe W, Varela O. Synthesis of antitumor-active (7S,9S)-4- demethoxy-7-O (2,6-dideoxy-2-iodo-a-L-manno-pyranosyl) adriamycinone: preparative resolution of a racemic anthracyclinone by alkoxyhalogenation of glycal. Carbohyd Res 130:C1-C3, 1984. e-Pub 1984.
219. Horton D, Priebe W. 14-esters of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl)adriamycinone: synthesis and antitumor activity. J Antibiot (Tokyo) 36(9):1211-5, 1983. e-Pub 1983. PMID: 6630080.
220. Horton D, Priebe W, Turner WR. Synthesis and antitumor activity of 7-0-(3,4-di-O-acetyl-2,6-dideoxy-a-L-lyxo-hexopyranosyl)adriamycinone. Carbohy Res 94:11-25, 1981. e-Pub 1981.
221. Horton D, Priebe W. New adriamycin analogs. Synthesis and antitumor activity of 14-substituted 7-O-(3,4-di-O-acetyl-2,6-dideoxy-a-L-lyxo-hexopyranosyl-daunomycinones. J Antibiot 34(8):1019-25, 1981. e-Pub 1981. PMID: 7319917.
222. Priebe W, Zamojski A. New approach to alkyl a-thioglycosides: cis- hydroxylation of alkyl 2,3-dideoxy-1-thio-glyc-2-enopyranosides. Polish J Chem 54:731-9, 1980. e-Pub 1980.
223. Horton D, Priebe W. Synthetic routes to higher-carbon sugars, reactions of lactones with 2-lithio-1,3-dithiane. Carbohyd Res 94:27-41, 1980. e-Pub 1980.
224. Priebe W, Zamojski A. The acid-catalyzed reaction of thiols with alkyl 2,3-dideoxy-glyc-2 enopyranosides or glycals. Tetrahedron 36:287-97, 1980. e-Pub 1980.
225. Grynkiewicz G, Priebe W, Zamojski A. Synthesis of alkyl 4,6-di-O- acetyl-2,3-dideoxy-a D-threo-hex-2-enopyranosides from 3,4,6-tri-O-acetyl- 1,5-anhydro-2-deoxy-D-lyxo-hex-1enitol. Carbohyd Res 68:33-41, 1979. e-Pub 1979.
226. Baranowska E, Priebe W, Zamojski A, Walocha K. Mass spectrometry of alkyl 6-amino 4,6-dideoxy-1-thio-a-D-L-lyxo-hexopyranosides. Polish J Chem 53:277-285, 1979. e-Pub 1979.
227. Chmielewski M, Mieczkowski J, Priebe W, Zamojski A, Adamowicz H. Configuration and conformation of methyl 2,3-anhydro-4-deoxy-pyranosides by 1H and 13C NMR Spectra. Tetrahedron 34:3325-30, 1978. e-Pub 1978.
228. Janota-Bassalik L, Pietraszek A, Priebe W. Studies Upon Resistance Factors in the Mammary Gland. Prace i Materialy Zootechniczne 2:59-72, 1973. e-Pub 1973.
229. Janota-Bassalik L, Zajac M, Pietraszek A, Priebe W. Ecological patterns of udder infection. Acta Microbiol Pol B 4:245-8, 1972. e-Pub 1972. PMID: 4566375.

Invited Articles

1. Priebe, W. Anthracycline Chemistry and Biology 1: Biological Occurrence and Biosynthesis, Synthesis and Chemistry. Journal of the American Chemical Society 131(23):8335, 2009. e-Pub 2009.

Other Articles

1. Pajak B, Zielinski R, Priebe W The Impact of Glycolysis and Its Inhibitors on the Immune Response to Inflammation and Autoimmunity. Molecules 29(6), 2024. PMID: 38542934.
2. Hughes EA, Zielinski R, Ray AE, Priebe W, Douglass Junior EF Development of a Novel Tool To Demystify Drug Distribution at Tissue-Blood Barriers. Chembiochem 24(13):e202200804, 2023. PMID: 36951632.
3. Dempke WCM, Zielinski R, Winkler C, Silberman S, Reuther S, Priebe W Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?. Eur J Cancer 185:94-104, 2023. PMID: 36966697.
4. Martinez-Castillo M, Altamirano-Mendoza I, Zielinski R, Priebe W, Pina-Barba C, Gutierrez-Reyes G Collagen matrix scaffolds: Future perspectives for the management of chronic liver diseases. World J Clin Cases 11(6):1224-1235, 2023. PMID: 36926129.
5. Pajak B, Zielinski R, Manning JT, Matejin S, Paessler S, Fokt I, Emmett MR, Priebe W The Antiviral Effects of 2-Deoxy-D-glucose (2-DG), a Dual D-Glucose and D-Mannose Mimetic, against SARS-CoV-2 and Other Highly Pathogenic Viruses. Molecules 27(18), 2022. PMID: 36144664.
6. Pajak B, Siwiak E, Soltyka M, Priebe A, Zielinski R, Fokt I, Ziemniak M, Jaskiewicz A, Borowski R, Domoradzki T, Priebe W 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents. Int J Mol Sci 1(1), 2019. PMID: 31905745.
7. Golonko A, Lewandowska H, Swislocka R, Jasinska UT, Priebe W, Lewandowski W Curcumin as tyrosine kinase inhibitor in cancer treatment. Eur J Med Chem 181:111512, 2019. PMID: 31404861.
8. Lin YH, Santani N, Hammoudi N, Ackroyd J, Khadka S, Yan V, Georgiou D, Sun Y, Zielinski R, Tran T, Pando S, Wang X, Maxwell D, Peng Z, Pisaneschi F, Mandal P, Leonard P, Xu Q, Wu Q, Jiang Y, Czako B, Kang Z, Asara J, Priebe W, Bornmann W, Marszalek J, DePinho R, Muller F Eradication of ENO1-deleted Glioblastoma through Collateral Lethality. bioRxiv, 2018.
9. Kalinowska M, Bielawska A, Lewandowska-Siwkiewicz H, Priebe W, Lewandowski W Apples: Content of phenolic compounds vs. variety, part of apple and cultivation model, extraction of phenolic compounds, biological properties. Plant Physiol Biochem 84C:169-188. PMID: 25282014.
10. Heimberger AB, Kong LY, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R The Role of Tregs in Human Glioma Patients and their Inhibition with a Novel STAT-3 Inhibitor. Clin Neurosurg 56(6):98-106, 2009. PMID: 20214040.
11. Witczak ZJ, Priebe W Carbohydrate chemistry. Current Organic Chemistry 12(12):972, 2008. PMID: 13852728.
12. Garnier-Suillerot A, Marbeuf-Gueye C, Salerno M, Loetchutinat C, Fokt I, Krawczyk M, Kowalczyk T, Priebe W Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action. Curr Med Chem 8(1):51-64, 2001. PMID: 11172692.
13. Portugal J, Martin B, Vaquero A, Ferrer N, Villamarin S, Priebe W Analysis of the effects of daunorubicin and WP631 on transcription. Curr Med Chem 8(1):1-8, 2001. PMID: 11172687.
14. Priebe W, Perez-Soler R Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol Ther 60(2):215-34, 1993. PMID: 8022858.

Abstracts

1. Kang Y, Zielinski R, Cardenas-Zuniga R, Venugopal R, Felix E, Grela K, Skora S, Nguyen V, Guzman V, Grybowski DJ, Peng S, Fokt I, Priebe W. Topoisomerase IIα, a Therapeutically Unexplored Target in PDAC: High in Vivo Efficacy of Annamycin, an Organotropic TOP2A Poison. The 7th JCA-AACR Special Joint Conference Secretariat, 2022. e-Pub 2022.
2. Zielinski R, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Felix E, Grybowski D, Priebe W. New approach to target metastatic colorectal cancer organotropism with L-Annamycin. Annual AACR meeting, New Orleans, 2022, 2022. e-Pub 2022.
3. Zielinski R, Grela K, Cardenas-Zuniga R, Fokt I, Venugopal R, Skora S, Poimenidou M, S-E LC, Ludwig J A, Priebe W. Targeting sarcoma pulmonary metastases with annamycin. CTOS 2021 Annual Meeting, Nov 10-13, 2021, 2021. e-Pub 2021.
4. Zielinski R, Grela K, Cardenas-Zuniga R, Poimenidou M, Remiszewski M, Felix E, Fokt I, Skora S, Priebe W. WP1874, a highly potent unique DNA binding agent with enhanced CNS uptake. Society of Neuro-Oncology 26th Annual Scientific Meeting, Nov 18-21, 2021 23(6):181, 2021. e-Pub 2021.
5. Zielinski R, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Poimenidou M, Eddine Lamhamedi-Cherradi S, Ludwig J, Priebe W. Annamycin, a novel non-cardiotoxic anthracycline with high activity against sarcomas metastatic to lungs. Molecular Targets and Cancer Therapeutics 20(12), 2021. e-Pub 2021.
6. Kang Y, Zielinski R, Cardenas Zuniga R, Venugopal R, Poimenidou M, Remiszewski M, Peng S, Felix E, GrelaK, Skora S, Nguyen V, Fokt I, Priebe W. Abstract PO-066: High uptake, retention, and in vivo activity of L-Annamycin in pancreatic cancer models 81(22), 2021. e-Pub 2021.
7. Zielinski R, Poimenidou M, Khuong M, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Gagea M, Swain J, Zhou S, Priebe W. Ketogenic diet (KD) and targeting Warburg effect: Apparent toxicity of KD combination with 2-deoxy-D-glucose. AACR-NCI-EORTC 20(12), 2021. e-Pub 2021.
8. Z T, Zielinski R, Grela K, Cardenas-Zuniga R, Skora S, Fokt I, Zal M A, Andreeff M, Gil L, Shephard R, Priebe, W. High Efficacy of Liposomal Annamycin (L-ANN) in Combination with Cytarabine in Syngeneic p53-Null AML Mouse Model. Blood 136, 2020. e-Pub 2020.
9. Zielinski R, Grela K, Skora S, Fokt I, Sander M, Didluch A, Priebe W. Liposomal Annamycin Inhibition of Lung Localized Breast Cancer. San Antonio Breast Cancer Symposium (SABC), 2020. e-Pub 2020.
10. Gil L, Shepard R C, Silberman S L, Zak E M, Priebe W. Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients. Blood 134(1), 2019. e-Pub 2019.
11. Zielinski R, Zal T, Grela K, Skora S, Fokt I, Sanders M, Remiszewski M, Felix E, Shanmugasundaram M, Priebe W. Dose and Schedule-Dependent Efficacy of Liposomal Annamycin in Pre-clinical Models of Acute Myeloid Leukemia. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. e-Pub 2019.
12. Sokolowska-Wojdylo M, Blazewicz I, Olszweska B, Zak E M, Klemp W, Silberman S L, Priebe, W. A Phase 1b Study Evaluating the Safety and Efficacy of Topical Administration of WP1220, an Inhibitor of STAT3 Activation, in Stage I, II or III Mycosis Fungoides (MF). Blood 134, 2019. e-Pub 2019.
13. Zielinski R, Grela K, Skora S, Jacamo R, Fokt I, Sanders M, Remiszewski M, Felix E, Shanmugasundaram M, Zal MA, Andreeff M, Priebe W, Zal T. Biodistribution and Efficacy of L-Annamycin in a Novel Imageable AML Mouse Model. American Society of Hematology (ASH), 2019. e-Pub 2019.
14. Ott M, Hashimoto Y, Marisetty A, Wei J, Zamler D, Leu JS, Kong LY, Fuller G, de Groot J, Priebe W, Sulman E, Heimberger A. Immunological reprogramming in the CNS tumor microenvironment and therapeutic efficacy of radiotherapy with STAT3 blockade. Society for Neuro-Oncology's Conference on Brain Metastases. e-Pub 2019.
15. Ott M, Hashimoto Y, Marisetty A, Wei J, Zamler D, Leu JS, Kong LY, Zhou S, Fuller G, de Groot J, Priebe W, Sulman E, Heimberger A. mlti-01.immunological reprogramming in the cns tumor microenvironment and therapeutic efficacy of radiotherapy with stat3 blockade. Neuro-Oncology Advances(Supplement_1):i14-i14, 2019. e-Pub 2019.
16. Zielinski R, Fokt I, Skora S, Felix E, Grela K, Arumugam J, Venugopal R, Ai M, Hartley G, Curran M, Priebe W. Abstract 4799: Inhibition of STAT3 in pancreatic ductal adenocarcinoma and immunotherapeutic implications. Cancer Research 79(13), 2019. e-Pub 2019.
17. Priebe W, Zielinski, R, Fokt I, Felix E, Aramugam J, Venugopal R, Khuong M, Krasinski M, Skora S. Design and evaluation of WP1122, an inhibitor of glycolysis with increased CNS uptake. Proceedings: 23rd Annual Meeting and Education Day, New Orleans, LA, November 15-18, 2018 20(6):86. e-Pub 2018.
18. Basu H, Wilganowski N, Lieblich J, Wu G, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe DJ, Wilding G. Abstract B091: Small-molecule inhibitors targeting a specific metabolic pathway for precision therapy of advanced castrate-resistant prostate cancer. Cancer Research 78(16), 2018. e-Pub 2018.
19. Basu H, Wilgonowski N, Lieblich J, Wu G, Fokt I, Ramachandran S, Yu J, Titus M, Priebe W, Beebe D, Wilding G. A metabolic pathway targeted inhibitor for precision therapy of castrate-resistant prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3846 78(13):Supplement, 2018. e-Pub 2018.
20. Zielinski R, Tworowska I, Skora S, Rusin A, Venugopal R, Arumugam J, Fokt I, Kang Y, Fleming J, Huang Y, Herpai D, Debinski W, Priebe W. Targeting IL-13RA2 in melanoma and pancreatic cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. (#1927) 78(13):Supplement, 2018. e-Pub 2018.
21. Gue C, Fokt I, Fahrenholtz S, Layman R, Priebe W, Cressman E. Alternatives to ethiodized oil in IR research: From biodiesel to radiopaque oily embolic agent. Proceedings: SIR Annual Scientific Meeting, 2018. e-Pub 2018.
22. Ferguson S, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, Zhang J, ibrahim N, de Groot J, McCarty J, O'brien B, Sawaya R, Verhaak R, Reddy S, Priebe W, Spetzler D, Heimberger A. CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. Neuro-Oncology, 2017. e-Pub 2017.
23. Fokt I, Skora S, Cybulski M, Zielinski R, Nguyen V, Felix E, Priebe W. Design, synthesis, and evaluation of 2-DG prodrugs and potentially useful in vivo inhibitors of glycolysis. Proceedings: Symposia on Cancer Research 2017 Cancer Metabolism, 2017. e-Pub 2017.
24. Michel, K, Zielinski R, Walker C, Schellingerhout D, Priebe W, Bankson J. Assessing the Efficacy of a Novel Glycolytic Inhibitor, WP1122, by Non-Invasive In Vivo Hyperpolarized Pyruvate MR Spectroscopy. Proceedings: Symposia on Cancer Research 2017 Cancer Metabolism, 2017. e-Pub 2017.
25. Zielinski R, Fokt I, Felix E, Khuong M, Krasinski M, Venugopal R, Arumugam J, Skora S, Priebe W. Preclinical evaluation of WP1122, a 2-DG prodrug and inhibitor of glycolysis. Proceedings: Symposia on Cancer Research 2017 Cancer Metabolism, 2017. e-Pub 2017.
26. Priebe W, Fokt I, Cybulski M, Conrad C, Madden T, Zielinski R, Rusin A. Latentiation of 2-Deoxy-D-glucose. European Journal of Cancer, Proceedings: 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Munich, Germany; Nov 29- Dec 2, 2016 68(Supplement 1), 2016. e-Pub 2016.
27. Zielinski R, Fokt I, Rusin A, Skora S, Priebe W. 2-Deoxy-2-halo-D-glucose derivatives inhibition of glycolysis in pancreatic cancer. Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA (#50) 76(14 Supplement). e-Pub 2016.
28. Priebe W. Exploring carbohydrate metabolism to target cancer: Derek Horton’s inspiration. Proceedings: 28th International Carbohydrate Symposium (ICS), New Orleans, LA, July 17-21, 2016 (#382). e-Pub 2016.
29. Fokt I, Cybulski M, Skora S, Priebe W. Synthesis of selectively acetylated 2-deoxy-D-glucoses, potential agents for treatment. Proceedings: 28th International Carbohydrate Symposium (ICS), New Orleans, LA, July 17-21, 2016 (#46). e-Pub 2016.
30. Priebe W. Targeting Pancreatic Cancer. Contemporary Oncology. Proceedings: 8th International Conference of Contemporary Oncology, Poznan, 16-18 March, 2016 19(Supplement 1), 2016. e-Pub 2016.
31. Conrad C, Fokt I, Madden T, Priebe W. An anthracycline analog, WP744, purposely designed to circumvent the blood-brain barrier appears to show activity in patients with recurrent high-grade gliomas in a Phase I study. Proceedings: 2015 SNO-SCIDOT Joint Conference, Nov 2015; San Antonio, TX, 2015. e-Pub 2015.
32. Hashimoto Y, Yaghi N, Wei J, Huang N, Ezhilarasan R, L-Y K, Zhou S, Chivukula P, Webb D, Priebe W, Payne J, Sulman E, Heimberger A. STAT3 inhibition enhances therapeutic efficacy of radiation treatment against established brain metastasis in murine melanoma model. Proceedings: 20th Annual Society for Neuro-Oncology Annual Scientific Meeting, Nov 19-22, 2015; San Antonio, TX, 2015. e-Pub 2015.
33. Zielinski R, Skora S, Rusin A, Fokt I, Heimberger A, Sawaya R, Priebe W. Combination of topoisomerase II poison Berubicin with STAT3 inhibitor WP1066 blocks potently tumor growth in GMB models. Proceedings: 20th Annual Society for Neuro-Oncology Annual Scientific Meeting, Nov 19-22, 2015; San Antonio, TX, 2015. e-Pub 2015.
34. Priebe W, Cybulski M, Fokt I, Conrad C. Design and Development of Monosaccharide-based Anticancer Drugs. Proceedings: 58th Annual Scientific Meeting of the Polish Chemical Society, Sept 21-25, 2015, Gdansk, Poland:470, 2015. e-Pub 2015.
35. Strozik T, Ozga M, Linke-Szewczyk A, Priebe W, Orlowski W, Derwinska K. Efficacy of 2-deoxy-D-glucose analog in glycolysis blocking in tumor cells. EJC -European journal of Cancer 51(Supplement 3):S5, 2015. e-Pub 2015.
36. Rusin A, Zielinski R, Fokt I, Nguyen V, Skora S, Jayakumar A, Priebe W. WP760, A new highly potent and selective agent against melanoma including BRAFi resistant melanoma. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA; Cancer Res 2015 75(suppl 15), 2015. e-Pub 2015.
37. Zielinski R, Rusin A, Madden T, Conrad C, Johansen M, Fokt I, Skora S, Jayakumar A, Heimberger A, Priebe W. Development of orally bioavailable formulation of WP1066 and its evaluation in vivo. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA; Cancer Res 2015 75(15 suppl), 2015. e-Pub 2015.
38. Jayakumar A, Venugopal R, Zielinski R, Rusin A, Fokt I, Skora S, Ni X, Duvic M, Priebe W. High sensitivity of cutaneous T-cell lymphoma (CTCL) to CABE, a component of propolis. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA; Cancer Res 2015 75(15 suppl), 2015. e-Pub 2015.
39. Priebe W, Jayakumar A, Radjendirane V, Fleming J, Rusin A, Zielinski R, Skora S, Kang Y, Fokt I. Transcriptional control of pancreatic cancer and small molecule modulators of transcription. Proceedings of the EACR-AACR-SIC 2015 Special Conference, 20-23 June 2015; Florence, Italy, 2015. e-Pub 2015.
40. Rusin A, Zielinski R, Fokt I, Nguyen V, Skora S, Jayakumar A, Priebe W. Development of novel therapies against BRAFi resistant melanomas. Proceedings of the GAP 2015 Conference, 14-16 April, 2015; Houston, TX, 2015. e-Pub 2015.
41. Tsourdinis G, Park H, Sun L, Fokt I, Jayakumar A, Zhang H, Cai Q, Zou D, Fang B, Priebe W, Wang M, Zhang L. Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo. Proceedings: 56th ASH Annual Meeting and Exposition, Dec 6-9, 2014, San Francisco, CA, 2014. e-Pub 2014.
42. Jayakumar A, Venugopal R, Fleming J, Kang Y, Rusin A, Zielinski R, Skora S, Fokt I, Priebe W. Status of STAT3, STAT5, and NF-κB in pancreatic cancer cell lines, small molecule inhibitors, and potential clinical implications. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA 74(21), 2014. e-Pub 2014.
43. Zielinski R, Rusin A, Priebe A, Arumugam J, Venugopal R, Skora S, Fokt I, Priebe W. STAT3/STAT5 blockade by WP1066 inhibits ovarian cancer cell proliferation and induces cell death. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA 74(21), 2014. e-Pub 2014.
44. Olbryt M, Rusin A, Fokt I, Habryka A, Sochanik A, Priebe W. Anti-melanoma activity of WP760 in various in vitro culturing conditions. Proceedings: 9th Int. Conf. of Anticancer Research 34(10):6086-6086, 2014. e-Pub 2014.
45. Priebe A, Rusin A, Zielinski R, Priebe W. Inhibition of STAT3 and STAT5 with WP1066 induces ovarian cancer cell. Proceedings of the 10th Biennial Ovarian Cancer Research Symposium, 2014. e-Pub 2014.
46. Fokt I, Krawczyk M, Kosinski S, Skora S, Cybulski M, Priebe W. Facile, selective one-pot synthesis of 4-O-benzylated glycals. 247th ACS National Meeting, Dallas, TX, 2014. e-Pub 2014.
47. Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W. D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose. 245th ACS National Meeting & Exposition, New Orleans, LA, United States, 2013. e-Pub 2013.
48. Jayakumar A, Rauvolfova J, Bao H, Fokt I, Skora S, Heimberger A, Priebe W. Blockade of HIF-1 with a small molecule inhibitor WP1066 in melanoma. AACR annual meeting 2013, 2013. e-Pub 2013.
49. Choi YA, Pandya H, Gibo DM, Fokt I, Priebe W, Debinski W. Nucleus-targeted doxorubicin as a potential therapy for glioblastoma. Neuro Oncology 15(3):iii37-iii61, 2013. e-Pub 2013.
50. Kong LY, Doucette TA, Ferguson S, Hachem J, Yang Y, Wei J, Priebe W, Fuller G, Qiao W, Rao G. Chemotherapeutic modulation of glioma development and invasion in vivo. Proceedings from the 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 15-18, 2012, Washington, D.C 14(6):27-27, 2012. e-Pub 2012.
51. Wang M, Sun L, Fokt I, Zhang L, Jayakumar A, Priebe W. Effect of berubicin, the 4'-o-benzylated doxorubicin analog, on growth inhibition and apoptosis in multiple myeloma. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2012. e-Pub 2012.
52. Sevier A, Zagorodna O, Martin S, Priebe W, Knudson M. Abstract LB-250: 2-Deoxy-D-glucose cytotoxicity relies on both glycolysis inhibition and ER stress induction, and is efficacious in a variety of human lymphoma models. Proceedings: AACR 103rd Annual Meeting 2012-- Mar 31-Apr 4, 2012; Chicago, IL 72(8), 2012. e-Pub 2012.
53. Kong L, Hatiboglu M, Wei J, Wang Y, McEnery K, Fuller G, Qiao W, Davies M, Priebe W, Heimberger A. The Influence of the Tumor Microenviroment Expression of P-STAT3 on Therapeutic Efficacy: CNS Tumors Preferentially Impacted. 16th Annual Scientific Meeting of the Society of Neuro-Oncology, 2011. e-Pub 2011.
54. Ahmed AA, Goldsmith J, Fokt I, Le X, Krzysko KA, Lesyng B, Bast Jr RC, Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemotherapy and Pharmacology, 2011. e-Pub 2011.
55. Rudak I, Lewandowska H, Kalinowska M, Priebe W, Lewandowski W. Anticancer properties of phenolic acids: cinnamic and bezoic acid derivatives. ESF-COST High-Level Research Conference, Systems Chemistry III, Crete, Greece, 2011. e-Pub 2011.
56. Wei J, Kong L, Doucette T, Wang Y, Wu A, Fuller G, Rao G, Priebe W, Heimberger A. Glioma-associated Cancer-initiating Cells Induce Immunosuppression. 242nd American Chemical Society National Meeting, 2011. e-Pub 2011.
57. Emmett MR, Wang X, Marshall A, Ji Y, Fokt I, Skora S, Conrad C, Priebe W. 2-Deoxy-D-Glucose Inhibits N-glycosylation in Glioblastoma-Derived Cancer Stem Cells. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL, 2011. e-Pub 2011.
58. Priebe, W. The Importance of Entrepreneurial Scientist for the Future of the American Economy. SE/SW ACS Meeting, 2010. e-Pub 2010.
59. Zhang L, Sun L, Qian J, Yang J, Priebe W, Yi Q, Wang M. Berubicin, a topoisomerase II poison with high CNS uptake, inhibits cell growth and induces apoptosis in diffuse large B-cell lymphomas. 22nd EORTC – NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics Conference, Berlin, Germany 8(7):180-181, 2010. e-Pub 2010.
60. He H, Emmett M, Marshal A, Ji Y, Conrad C, Priebe W, Colman H, Lang F, Madden T. Induced Phenotypic Differentiation of Glioblastoma Stem Cells Revisited - Dectection of Glycomic Response Based on Metabolic Labeling. 15th Annual SNO conference, Montreal, Canada, 2010. e-Pub 2010.
61. Conrad C, Madden T, Ji Y, Colman H, Priebe W. Berubicin: A novel anthracyline with high CNS uptake shows strong preclinical activity in both ependymoma cell lines and cancer stem-like cell line models. 15th Annual SNO conference, Montreal, Canada, 2010. e-Pub 2010.
62. Wang M, Sun L, Fokt I, Bao H, Zhang L, Jayakumar A, Priebe W. Berubicin, a novel mechanistically altered anthracycline potently inhibits cell growth and induces apoptosis in mantle cell lymphoma. European Journal of Cancer Supplements 8(7):182, 2010. e-Pub 2010.
63. Priebe W, Sun L, Fokt I, Zhang L, Jayakumar A, Zhang X, Madden T, Wang M. Berubicin, a topoisomerase II poison with high CNS uptake, potently inhibits cell growth and induces apoptosis in diffuse large B-cell lymphomas. 22nd EORTC – NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics Conference, Berlin, Germany 8(7):182, 2010. e-Pub 2010.
64. Wu A, Wei J, Kong Y, Priebe W, Sawaya R, Heimberger A. Glioma Cancer stem cells induce immune suppressive macrophages. 15th Annual SNO conference, Montreal, Canada, 2010. e-Pub 2010.
65. Kong LY, Doucette T, Wei J, Priebe W, Sawaya R, Yang J, Rao G, Heimberger A. Novel murine models of immune competent spontaneously-arising heterogeneous gliomas for evaluation the new classes of chemoimmunotherapies. 15th Annual SNO conference, Montreal, Canada, 2010. e-Pub 2010.
66. Chumbalkar V, Arumugam J, Dao L, Baggerly K, Priebe W, Bogler O. Phosphoproteomic analysis of novel JAK/STAT inhibitors in glioma cells. 15th Annual SNO conference, Montreal, Canada, 2010. e-Pub 2010.
67. Emmett M, Wang X, Marshall A, Ji Y, Fokt I, Skora S, Conrad C, Priebe W. 2-Deoxy-D-glucose inhibits n-glycosylation in glioblastoma-derived cancer stem cells. 15th Annual SNO conference, Montreal, Canada, 2010. e-Pub 2010.
68. Wei J, Wu A, Kong LY, Wang Y, Priebe W, Heimberger A. Hypoxia potentiates GBM-mediated innate and adaptive immune suppression. 15th Annual SNO conference, Montreal, Canada, 2010. e-Pub 2010.
69. Wu A, Wei J, Kong LY, Wang Y, Priebe W, Sawaya R, Lang F, Heimberger A. Glioma cancer stems cells induce immune suppressive macrophages. 100th AACR Annual Meeting, Washington DC, 2010. e-Pub 2010.
70. Priebe W. Glycolysis: Chemistry, Biology, and Therapeutic Ramification. 101st ACS Annual Meeting, San Francisco, CA, 2010. e-Pub 2010.
71. Priebe, W. Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia. 51st ASH Annual Meeting and Exposition, 2009. e-Pub 2009.
72. Priebe W, Cybulski C, Fokt I, Skora S, Conrad CA, Madden T. Blocking glycolysis with 2-deoxy-D-glucose prodrugs to target brain tumors: A novel concept. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Boston, MA, 2009. e-Pub 2009.
73. Madden T, Johansen MJ, Thapar J, Conrad C, Fokt I, Priebe W. WP769, An orally bioavailable blood brain barrier penetrating anthracycline. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Boston, MA, 2009. e-Pub 2009.
74. Kong LY, Wei J, Gelbard A, Wang T, Wei Q, Fokt I, Overwijk W, Priebe W, Heimberger A. STAT3 Blockade Enhances IFN-alpha Immunotherapy for Intracerebral Malignancy. Neuro-Oncology 11(5):615, 2009. e-Pub 2009.
75. Koul D, Fokt I, Guan S, Conrad C, Madden T, Yang WK, Priebe W. Berubicin: A Novel Topoisomerase II Inhibitor with Activity in Ependymoma. Neuro-Oncology 11(5):640, 2009. e-Pub 2009.
76. Conrad C, Koul D, Guan S, Fokt I, Shen R, Ramnarian D, Madden T, Yung WKA, Atkinson J, Gilbertson R, Priebe W. Berubicin: a novel topoisomerase II Inhibitor with activity in ependymoma. 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, 2009. e-Pub 2009.
77. Conrad C, Madden T, Sheng X, Priebe W. Galectins and their role in high-grade glioma tumor progression. 238th ACS National Meeting, Wolfrom/Isbell/New Investigator Symposium, 2009. e-Pub 2009.
78. Priebe, W. Drug discovery in academia: A chemist in the biologist's cookie jar. 238th ACS National Meeting, Wolfrom/Isbell/New Investigator Symposium, 2009. e-Pub 2009.
79. Swiatek-Machado K, Ellert-Miklaszewska A, Szeja W, Priebe W, Grynkiewicz G, Lesyng B, Kaminska B. Evaluation of antitumor activity of novel inhibitors of JAK/STAT3 pathway in glimoa cells. 34th Congress of the Federation-of-European-Biochemical-Societies, FEBS Journal, Prage CZECH Republic 276:392-392, 2009. e-Pub 2009.
80. Colman H, Conrad CC, Sai K, Wang S, Popoff S, Aldape K, Lang F, Fokt I, Madden TL, Yung WKA, Priebe W. WP1193 inhibits JAK2/STAT3 pathway, blocks self-renewal and induces apoptosis in glioblastoma cancer stem cells. 100th American Association for Cancer Medicine Annual Meeting, 2009. e-Pub 2009.
81. Ahmed AA, Fokt I, Krzysko K, Lesyng B, Jr BR, Priebe W. Unsaturated glycoside of genistein induces severe microtubule depolymerization and mitotic arrest in ovarian cancer cells. 100th American Association for Cancer Research Annual Meeting, 2009. e-Pub 2009.
82. Rogers JC, Krastins B, Berry R, Priebe W, Dillon R, Sarracino D, Rosenblatt MM, Kilmer G, Dobbs M, Feather-Henigan K, Devakumar A, Major M, Kaboord BJ, Webb B, Lopez M, Nilsson CL, Lang FF, Colman HC, Conrad CA. Quantitative phosphoproteomic analysis of STAT3/IL-6/HIF1a signaling partners in NS11 glioblastoma stem cells with multiplexed tandem mass tags and a novel rapid Western blotting technique. 100th American Association for Cancer Research Annual Meeting, 2009. e-Pub 2009.
83. Samanta A, Chakraborty S, Samanta S, Wang Y, Sun X, Schlette E, Priebe W, Arlinghaus R. Disruption of the Bcr-Abl/Jak2/HSP90 Network Complex Leading to Induction of Apoptosis in Drug-Resistant CML Cells by a New Compound WP1193. Blood 112(11):1098, 2008. e-Pub 2008.
84. Antonovic L, Fokt I, Johansen MJ, Szymanski S, Skora S, Conrad CA, Madden T, Priebe W. A novel monosaccharide-based antimetabolite 2,2-difluoro-D-glucose (2-DFG) blocks glycolysis and induces cell death in gliomas. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 2008. e-Pub 2008.
85. Kazerooni R, Conrad C, Johansen MJ, Sakamoto M, Fokt I, Schroeder C, Thapar N, Meyer C, Priebe W, Madden T. Hematologic pharmacodynamics linked to the pharmacokinetics of berubicin (B), a blood-brain barrier penetrating anthracycline active against high grade glioma, in phase 1/11 clinical trials. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland 6(12):187-188, 2008. e-Pub 2008.
86. Heimberger AB, L-Y K, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Wei J, Qiao W, Schmittling RJ, Archer GE, Sampson JH, Hiraoka N, Priebe W, Fuller GN, Sawaya R. The Role of Tregs in Human Glioma Patients and their Inhibition with a Novel STAT-3 Inhibitor. 2008 Congress of Neurological Surgeons Annual Meeting, 2008. e-Pub 2008.
87. Colman H, Sai K, Wang S, Popoff S, Aldape KD, Lang FF, Conrad CA, Madden T, Yung A, Priebe W. Effect of a small molecule inhibitor of the JAK2/STAT3 pathway on self-renewal of glioblastoma stem cells. 2008 ASCO Annual Meeting, Chicago, IL, 2008. e-Pub 2008.
88. Heimberger AB, Sun W, Kong L, Abou-Ghazal M, Wei J, Gumin J, Colman H, Priebe W, Lang FF. Glioblastoma multiforme stem cells mediate immune suppression that can be inhibited with JAK2/STAT3 Blockage. 2008 ASCO Annual Meeting, Chicago, IL, 2008. e-Pub 2008.
89. Conrad CA, Sheng X, Ji Y, Howard C, Emmett M, Lang F, Aldape K, Priebe W, Madden T, Nilsson C. Galectin-1 expression in glioblastoma cell lines is associated with p53 gene expression: Implications with cell survival, invasive phenotype, presence in CD133 glioma cancer-stem cells (CSC) and poor patient survival. AACR Annual Meeting 2008, 2008. e-Pub 2008.
90. Kong LY, Abou-Ghazal MK, Chakraborty A, Fuller G, Madden T, Qiao W, Grimm EA, Priebe W, Heimberger AB. Small molecule inhibition of Stat3 enhances survival in mice with intracerebral melanoma. AACR Annual Meeting 2008, San Diego, CA, 2008. e-Pub 2008.
91. Priebe W, Madden T, Conrad CA. Berubicin, a Brain Tumor Targeting Anthracycline: Discovery and Clinical Evaluation. AACR Annual Meeting 2008, 2008. e-Pub 2008.
92. Antonovic L, Fokt I, Szymanski S, Conrad CA, Johansen MJ, Madden TL, Priebe W. 2-Deoxy-2-fluro-D-manose induces type II cell death in gliomas. AACR Annual Meeting 2008, San Diego, CA, 2008. e-Pub 2008.
93. Kazerooni R, Schroeder C, Conrad C, Johansen M, Sakamoto M, Fokt I, Thapar N, Meyer C, Priebe W, Madden T. Metabolite pharmacokinetics of berubicinol (BRB-ol), the 13-hydroxy metabolite of RTA744 (berubicin(BRB)), a blood-brain barrier penetrating anthracycline active against high grade glioma, in phase I/II clinical trials. AACR Annual Meeting 2008, 2008. e-Pub 2008.
94. Samanta AK, Chakroborty SN, Wang Y, Cortes J, Priebe W, Arlinghaus RB. Down-regulation of HSP90 expression by caffeic acid derivative WP1193 induced apoptosis in imatinib-sensitive/-resistant BCR-ABL+ cells by inducing degradation Bcr-Abl/Jak2 signaling proteins. AACR Annual Meeting 2008, San Diego, CA, 2008. e-Pub 2008.
95. Guha S, Chakraborty A, Kunnumakkara A, Szymanski S, Fokt I, Abbruzzese J, Aggarwal B, Madden T, Priebe W. A novel JAK2-STAT3 inhibitor blocks mitogenesis and angiogenesis in pancreatic cancer. AACR Annual Meeting 2008, San Diego, CA, 2008. e-Pub 2008.
96. Setny P, Lesyng B, Priebe W. Modeling a Novel Binding Mode of JAK2 Substrate Competitive Inhibitors. Keystone Symposia on Molecular and Cellular Biology, Computer-Aided Drug Design, Santa Fe, New Mexico, 2008. e-Pub 2008.
97. Madden T, Xu QA, Thapar J, Johansen M, Priebe W, Kazerooni R. A new era of liquid chromatography: Immediate effects of high throughput analysis on drug development and therapeutic drug monitoring. PITTCON, 59th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, New Orleans, Louisiana, 2008. e-Pub 2008.
98. Setny P, Lesyng B, Priebe W. Modeling a Novel Binding Mode of JAK2 Substrate Competitive Inhibitors. Keystone Symposia on Molecular and Cellular Biology, Computer-Aided Drug Design, 2008. e-Pub 2008.
99. Jackson CBJ, Judd L, Menheniott T, Priebe W, Howlett M, Giraud A. A novel inhibitor of STAT3 as a therapeutic against augmented gp130 signaling in human gastric cancer. 20th Lorne Cancer Center Conference Proceedings:261, 2008. e-Pub 2008.
100. Kazerooni R, Conrad C, Schroeder C, Johansen M, Sakamoto M, Thapar N, Meyer C, Priebe W, Madden I. Phase I clinical pharmacokinetics of RTA 744 (berubicin(B)), a blood-brain barrier penetrating anthracycline active against high grade glioma, and evaluation of its 13-hydroxy metabolite, berubicinol (B-o1). Molecular Cancer Therapeutics, San Francisco, CA 6(12):3465S-3466S, Part 2, 2007. e-Pub 2007.
101. Leopsava A, Johansen M, Fokt I, Szymanski S, Conrad C, Priebe W, Madden T. 2-Deoxy-D-glucose induces Type II cell death in pancreatic cancer. Molecular Cancer Therapeutics, San Francisco, CA 6(12):3443S-3443S Part 2, 2007. e-Pub 2007.
102. Schroeder CP, Fokt I, Johansen M, Rhea R, Allen TL, Madden T, Priebe W. WP760, a New DNA-binding agent with unique melanoma selectivity. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA 6(12):3407S-3407S, Part 2, 2007. e-Pub 2007.
103. Colman H, Priebe W, Popoff S, Aldape K, Wang S, Conrad C, Lang F, Sai K, Yung A. Regulation of Glioblastoma Stem Cell Self-Renewal by Stat3, 2007. e-Pub 2007.
104. Leposava A, Fokt I, Szymanski S, Conrad C, Priebe W, Madden T. Inhibition of glycolysis and induction of autophagy in gliomas by 2-fluro-deoxy-D-glucose. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA B34, 2007. e-Pub 2007.
105. Kong LY, Hussain SF, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of STAT3 reverses immune tolerance in malignant glioma patients. Neuro-Oncology 12th Annual Scientific Meeting, Dallas, TX 9(4):507-507, 2007. e-Pub 2007.
106. Guha S, Chakraborty A, Kunumakkara AB, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Aggarwal BB, Madden T, Priebe W. WP1066, a potent inhibitor of JAK2-STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. Gastrointestinal Cancer Research 2(4):205-208, 2007. e-Pub 2007.
107. Klostergaard J, Tang D, Priebe W. Cytotoxic Paclitaxel Analogues for Conjugation to Targeted Scaffolds as Novel Prostate Cancer Therapeutics. DOD Prostate Cancer Research Program sponsored Innovative Minds in Prostate Cancer Treatment (IMPaCT), Atlanta, GA, 2007. e-Pub 2007.
108. Priebe, W. Glycal-based syntheses of biologically important molecules. 234th ACS National Meeting, Boston, MA, 2007. e-Pub 2007.
109. Kazerooni R, Conrad C, Baud C, Johansen M, Thapar N, Meyer C, Priebe W, Madden T. Phase I clinical pharmacokinetics of RTA 744: a blood brain barrier penetrating anthracycline active against high grade glioma. ASCO, Chicago, IL, 2007. e-Pub 2007.
110. Conrad C, Maher E, Cloughesy T, Groves M, Gilbert M, Madden T, Levin V, Priebe W, Meyer C, Yung W. Final results of a Phase I trial with the novel anthracycline derivative RTA 744 in patients with primary brain tumors. ASCO, Chicago, IL, 2007. e-Pub 2007.
111. Priebe W, Madden T, Charles C, Yongjie J, Sigmond H, Fokt I, Frederick L. 2-Deoxy-D-glucose: Old molecule, new brain tumor agent inducing autophagy. 2007 AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
112. Madden T, Johansen M, Conrad C, Kazerooni R, Fokt I, Thapar N, Meyer C, Priebe W. WP769: An orally bioavailable topo II poison with activity against brain tumors. 2007 AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
113. Chakraborty A, Guha S, Helgason T, Szymanski S, Fokt I, Kazerooni R, Madden T, Priebe W. A novel Jak2/STAT3 pathway inhibitor promotes apoptosis and blocks growth of bladder cancer cells. 2007 AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
114. Bidwell G, Davis A, Fokt I, Priebe W, Raucher D. An elastin0like polypeptide – Doxorubicin fusion for thermally-targeted delivery and evasion of multidrug resistance. 2007 AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
115. Guha S, Chakraborty A, Szymanski S, Fokt I, Abbruzzese J, Kazerooni R, Madden T, Priebe W. WP 1066, a potent inhibitor of Jak2/STAT3 pathway inhibits pancreatic tumor growth both in vitro and in vivo. 2007 AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
116. Samanta A, Kantarjian H, Priebe W, Arlinghaus R. Cross talk between Jak2 and Lyn in Bcr-Abl signaling pathway in cells from Imatinib-sensitive and resistant chronic myelogenous leukemia (CML). 2007 AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
117. Kazerooni R, Conrad C, Baud C, Johansen M, Thapar N, Meyer C, Culotta K, Priebe W, Madden T. Phase 1 clinical pharmacokinetics of RTA 744: a blood brain barrier penetrating anthracycline active against high grade glioma. 2007 AACR Annual Meeting, Los Angeles, CA, 2007. e-Pub 2007.
118. Priebe W. Exploring carbohydrates to design blood-brain barrier-penetrating, brain tumor-targeting anthracyclines. 233rd American Chemical Society National Meeting, Chicago, IL, 2007. e-Pub 2007.
119. Fokt I, Krawczyk M, Skibicki P, Grynkiewicz G, Priebe W. Sugar moiety-fluorinated anthracyclines. 233rd American Chemical Society National Meeting, Chicago, IL, 2007. e-Pub 2007.
120. Kazimierski A, Shailubhai K, Picker D, Priebe W. Novel Analogs of Atiprimod for targeting multiple myeloma. 233rd American Chemical Society National Meeting, Chicago, IL, 2007. e-Pub 2007.
121. Priebe W, Madden T, Fokt I, Johansen M, Conrad C. Modular design of DNA Binding Agents Capable of penetrating Blood-Brain Barrier and Targeting Brain Tumors. American Association for Cancer Research-American Chemical Society Joint Conference – Chemistry in Cancer Research: A Vital Partnership, San Diego, CA, 2007. e-Pub 2007.
122. Schroeder C, Fokt I, Kazerooni R, Johansen M, Priebe W, Madden T. WP760, a DNA Binding Agent with Unique Melanoma Selectivity Induces Apoptosis. 7th Joint Conference AACR & JCA in the Forefront of Basic and Translational Cancer Research, Waikoloa, Hawaii, 2007. e-Pub 2007.
123. Conrad C, Madden T, Maher E, Cloughesy T, Meyer C, Priebe W, Baud C, Fokt I, Gilbert M, Groves M, Levin V, Yung WKA. Preliminary Results of an Accelerated Dose Escalation Phase 1 Trial with the Novel Anthracycline Derivative (RTA 744) in Patients with Primary Brain Tumors. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, 2006. e-Pub 2006.
124. Priebe W, Fokt I, Szymanski S, Bao J, Conrad C, Chakraborty A, Abbruzzese J, Guha S, Myers J, Madden T. Novel small molecule inhibitors of Jak2/STAT3 pathway: design, structure-activity relationship, and oral bioavailability. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, 2006. e-Pub 2006.
125. Fokt I, Priebe W. Synthesis of WP744/RTA744, a New Blood-Brain Barrier (BBB) Penetrating Anthracycline. 62nd SW ACS Regional Meeting, 2006. e-Pub 2006.
126. Conrad, CA, Meyer C, Madden T, Priebe W, Lang FF. Survival study of RTA 744 (currently a single agent phase 1 study) along and in combination with temozolomide in orthotopic model of glioma. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, J of Clinical Oncology 24(18S):1556, 2006. e-Pub 2006.
127. Priebe W, Fokt I, Szymanski S, Madden T, Bao JI, Lesyng B, Conrad C, Kupferman M, Abbruzzese J, Myers J. Design, Synthesis and Structure-Activity Relationships of Novel Jak2/STAT3 Signaling Inhibitors. 97th AACR Annual Meeting, 47: LB-298, 2006. e-Pub 2006.
128. Madden T, Kazerooni R, Myers J, Culotta K, Donato N, Johansen M, Kondo Y, Mack D, Priebe W. The precilincal pharmacology of WP1066, a potent small molecule inhibitor of the JAK2/STAT3 pathway. 97th AACR Annual Meeting 47, 2006. e-Pub 2006.
129. Kupferman ME, Zhou G, Zhao M, Jasser S, Daka-Yazici Y, Priebe W, Myers J. A novel inhibitor of STAT3 signaling in Head and neck squamous cell carcinoma. 97th AACR Meeting 47, 2006. e-Pub 2006.
130. Ferrajoli A, Faderl S, Wang T, Priebe W, Kantarjian H, Talpaz M, Estrov Z. WP1066: A Novel PI-3K Inhibitor with Antileukemic Activity in Philadelphia Chromosome-Positive ALL. Abstract 850, 47th Annual Meeting of American Society of Hematology, Atlanta, GA, 2005. e-Pub 2005.
131. L-Y K, Kapuria V, Bartholomeusz G, Talpaz M, Priebe W, Donato NJ. Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. 47th Annual Meeting of American Society of Hematology, GA, Abstract 1489, 2005. e-Pub 2005.
132. Bartholomeusz GA, Donato N, EstrovZ, Priebe W, Talpaz M. Activation of a Novel Proteasomal Independent Bcr/Abl Degradation Pathway by WP1130 Induces Apoptosis in CML Cells. 47th Annual Meeting of American Soc Hemat, Atlanta, GA, Abstract 2862, 2005. e-Pub 2005.
133. Thapar N, Priebe W, Johansen MJ, Fokt I, Thapar J, Meyer C, Conrad CA, Madden T. Summary of the Preclinical Pharmacology of RTA 744 (WP744): A New Topo II Inhibitor in Phase I Development. AACR-NCI-EORTC International Conference, Philadelphia, 2005. e-Pub 2005.
134. Bartholomeusz GA, Donato N, Estrov Z, Priebe W, Talpaz M. Activation of a novel proteasomal independent Bcr/Abl degradation pathway by WP1130 induces apoptosis in CML cells. Blood 106 (11): 802A-802A 2862 Part 1, 2005. e-Pub 2005.
135. Iwamaru A, Szymanski S, Fokt I, Hess KR, Sawaya R, Kondo S, Priebe W, Kondo Y. Inhibition of STAT3 signaling by WP1066, a novel tyrosine kinase inhibitor in malignant glioma cells in vivo. AACR-NCI-EORTC International Conference, Philadelphia, 2005. e-Pub 2005.
136. Kong LY, Kapuria V, Bartholomeusz G, Priebe W, Talpaz M, Donato N. Antitumor activity and mechanism of action of a novel Stat3 inhibitor, WP1066, against human B-cell non-Hodgkin's lymphoma and multiple myeloma. Blood 106 (11): 429A-429A 1489 Part 1, 2005. e-Pub 2005.
137. Ferrajoli A, Faderl S, Wang T, Priebe W, et al. WP1066: A novel PI-3K inhibitor with antileukemic activity in Philadelphia chromosome-positive ALL. Blood 106 (11): 250A-251A 850 Part 1, 2005. e-Pub 2005.
138. Fokt I, Conrad C, Madden T, Yung AW, Lang FF, Thapar N, Priebe W. The discovery and Development of Blood-Brain Barrier (BBB) Penetrating Anthracyclines for the Treatment of Brain Tumors. AACR-NCI-EORTC International Conference, Philadelphia, 2005. e-Pub 2005.
139. Bao YI, Fokt I, Szymanski S, Madden T, Conrad C, Abbruzzese J, Priebe W. Inhibition of Consititutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic cancer cells. AACR-NCI-EORTC International Conference, Philadelphia, 2005. e-Pub 2005.
140. Fanale MA, Liu Y, McKenzie TS, Priebe W, et al. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. J Clinical Oncology 23(16): 155S-155S Part 1 Suppl. S 06/01/2005, 2005. e-Pub 2005.
141. Iwamaru A, Szymanski SP, Fokt I, Priebe W, et al. Inhibition of STAT3 signaling by WP1066, a novel tyrosine kinase inhibitor in malignant glioma cells in vitro and in vivo. Clinical Cancer Res 11 (24): 9021S-9021S, 2005. e-Pub 2005.
142. Bao JJ, Fokt I, Szymanski S, Priebe W, et al. Inhibition of constitutively active STAT3 by WP1066 suppresses proliferation and induces apoptosis in pancreatic cancer cells. Clinical Cancer Res 11 (24): 9026S-9027S, 2005. e-Pub 2005.
143. Thapar NC, Priebe W, Johansen MJ, et al. Summary of the preclinical pharmacology of RTA 744 (WP744): A new topo II inhibitor in phase I development. Clinical Cancer Res11 (24): 9019S-9020S, 2005. e-Pub 2005.
144. Fanale MA, Liu TS, McKenzie TS, Fokt I, Priebe W, Hunt KK. Investigation of whether expression of bcl-2 influences the apoptotic response of doxorubicin-resistant breast cancer cells to a novel anthracycline. ASCO Annual Meet, Florida, 2005. e-Pub 2005.
145. Lee S, Fokt I, Grossman HB, Czerniak B, Dinney C, Priebe W. WP744, a novel anthracycline highly active against wild-type and doxorubicin-resistant bladder cancer cell lines. Proc 96 Am Assoc Cancer Res, 46: 2389, 2005. e-Pub 2005.
146. Fokt I, Conrad CA, Madden T, Priebe W, et al. The discovery and development of blood-brain barrier (BBB) penetrating anthracyclines for the treatment of brain tumors. Clinical Cancer Res11 (24): 9013S-9013S, 2005. e-Pub 2005.
147. Ferrajoli A, Faderl S, Van Q, Harris D, Priebe W, Kantarjian H, Talpaz M, Estrov Z. WP1066, a Next Generation Member of JAK-STAT Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells. Abstract 1169, 46th Annual Meeting of American Society of Hematology, San Diego, CA, 2004. e-Pub 2004.
148. Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov A. WP1034, a Novel Jak-Stat Inhibitor, Has Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML) Cell Lines and AML Patient Samples. Abstract 2528, 46th Annual Meeting of American Society of Hematology, San Diego, CA, 2004. e-Pub 2004.
149. Thapar N, Meyer C, Huff W, Culotta K, Fokt I, Priebe I, Madden T, Johansen M. Assessment of the therapeutic activity and dose optimization for the anthracycline RTA 744 (WP744) using a xenograph model. Elsevier, EJC Supplements; Proceedings: 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, geneva, Switzerland, October 2004 2(8), 2004. e-Pub 2004.
150. Krawczyk M, Kosinski S, Fokt ID, Priebe W. Selective benzylation of glycals. Abstracts of Papers, 228th ACS National Meeting, CARB-53; Philadelphia, 2004. e-Pub 2004.
151. Fokt ID, Mironiuk E, Dominiak P, Pastuch G, Wozniak K, Priebe W. Facile synthesis of 14-, 16-, and 18-member macrocycles from configurationally diverse sugars. 228th ACS National Meeting, CARB-51; Philadelphia, 2004. e-Pub 2004.
152. Priebe W. Biological importance of the sugar moiety in anthracycline antibiotics and related DNA binders. 228th ACS National Meeting, CARB-17; Philadelphia, 2004. e-Pub 2004.
153. Fokt ID, Mironiuk E, Dominiak P, Pastuch G, Wozniak K, Priebe W. Facile synthesis of 14-, 16-, and 18-member macrocycles from configurationally diverse sugars. Abstracts of Papers, 228th ACS National Meeting, CARB-51; Philadelphia, 2004. e-Pub 2004.
154. Priebe W. Biological importance of the sugar moiety in anthracycline antibiotics and related DNA binders. . Abstracts of Papers, 228th ACS National Meeting, CARB-17; Philadelphia, 2004. e-Pub 2004.
155. Fokt ID, Kowalczyk-Przewloka T, Skora S, Kosior M, Pastuch G, Wandzik I, Grynkiewicz G, Szeja W, Priebe W. Practical synthesis of WP744, a brain tumor-targeting anthracycline. Abstracts of Papers, 228th ACS National Meeting, CARB-52; Philadelphia, 2004. e-Pub 2004.
156. Thapar NC, Johansen MJ, Conrad C, Priebe W, Thapar J, Fokt I, Culotta KS, Madden TL. CNS distribution of WP744: A novel anthracycline with activity against glioblastoma multiforme. Proc. 95 Am. Assoc. Cancer Res., Orlando, FL 45: 358, 2004. e-Pub 2004.
157. Donato NJ, Wu J, Kong LY, Meng F, Priebe W, Talpaz M. Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia. Abstract 2964, 2004. e-Pub 2004.
158. Fokt ID, Kowalczyk-Przewloka T, Skora S, Kosior M, Pastuch G, Wandzik I, Grynkiewicz G, Szeja W, Priebe W. Practical synthesis of WP744, a brain tumor-targeting anthracycline. 228th ACS National Meeting, CARB-52; Philadelphia, 2004. e-Pub 2004.
159. Krawczyk M, Kosinski S, Fokt ID, Priebe W. Selective benzylation of glycals. 228th ACS National Meeting, CARB-53; Philadelphia, 2004. e-Pub 2004.
160. Ferrajoli A, Keating MJ, Van Q, Harris DM, Donato NJ, Priebe W, Kantarjian HM, Talpaz M, Levitzki A, Estrov Z. The Protein Kinase Inhibitor AG1801 Abrogates Constitutive STAT3 Phosphorylation, Suppresses Colony-Forming Cell Proliferation, and Activates the Apoptotic Pathway in Chronic Lymphocytic Leukemia (CLL). Abstract 810, 46th Annual Meeting of American Society of Hematology, San Diego, CA, 2003. e-Pub 2003.
161. Kong LY, Talpaz M, Priebe W, Levitzki A, Aggarwal B, Fokt I, Szymanski S, Donato NJ. Novel Tyrphostin Analogues Inhibit Stat3 Activation and Induce Apoptosis in Multiple Hematological Malignancies. Abstract 4534, 46th Annual Meeting of American Society of Hematology, San Diego, CA, 2003. e-Pub 2003.
162. Priebe W, Kosinski S. Highly effective magnesium catalyzed deacetylation in methanol. Abstracts of Papers, 226th ACS National Meeting, CARB-032; New York, NY, 2003. e-Pub 2003.
163. Fokt ID, Priebe W, Grynkiewicz G. NYSynthesis of WP744, a novel highly apoptotic anticancer agent. 226th ACS National Meeting, CARB-064; New York,, 2003. e-Pub 2003.
164. Priebe W, Evrony G, Fokt I, Lee S, Talpaz M, Donato NJ. WP744, A novel highly apoptotic and anti-proliferative agent against STI-571-resistant leukemic cells. 3rd International Conference on Inhibitors of Protein Kinases, Warsaw, 2003. e-Pub 2003.
165. Thapar NC, Scholz CR, Fokt I, Johansen MJ, Pang J, Culotta KS, Priebe W, Madden TL. Preclinical investigation of oral bioavailability, pharmacokinetics, and tissue distribution of WP769, a new potent topoisomerase II poison. Proc. Am. Assoc. Cancer Res-EORTC-NCI, #C249:243, 2003. e-Pub 2003.
166. Inge TH, Harris NL, Azizkhan RG, Wu J, Fokt I, Priebe W. WP744 overcomes doxorubicin resistance in neuroblastoma cells. Proc 94 Am Assoc Cancer Res. (2nd ed) 44: 1616, 2003. e-Pub 2003.
167. Priebe W, Fokt I, Lee S, Yung WKA, Lang FF, Madden TL, Conrad C. Targeting glioblastoma with new DNA-binding agents. Proc Am Assoc Cancer Res-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics, #A159:243, 2003. e-Pub 2003.
168. Wu Q, Vega J, Cao X, Wallace S, Fokt I, Priebe W, Li C. Antitumor activity of doxorubicin (DOX)-bound polyethylene glycol-poly(L-glutamic acid) (PEG-PG) block copolymer with amide and ester linkages. Proc 94 Am Assoc Cancer Res. (2nd ed) 44: 1656, 2003. e-Pub 2003.
169. Madden TL, Scholz CR, Johansen MJ, Thapar NC, Fokt I, Rhea R, Priebe W. Preclinical pharmacokinetics of WP744, a novel promising anticancer agent. Proc. Am. Assoc. Cancer Res-EORTC-NCI, #C249:245, Boston, 2003. e-Pub 2003.
170. Maher J, Krishan A, Savaraj N, Priebe W, Lampidis TJ. Increased effects of 2-D-glucose on cell progression and death in R° vs wild type osteosarcoma cells. Proc 94th Am Assoc Cancer Res. (2nd ed) 44: 5565, 2003. e-Pub 2003.
171. Scholz CR, Thapar NC, Johansen MJ, Fokt I, Culotta KS, Priebe W, Madden TL. A sensitive and specific method for the determination of WP744, a mechanistically alterted anthracycline in mouse, rat, dog, and human plasma by LC/MS/MS. Proc Am Assoc Cancer Res-EORTC-NCI, #C241:243, 2003. e-Pub 2003.
172. Brooks TA, Vredenburg M, Pera P, Fokt I, Priebe W, Bernacki RJ. WP744, an anthracycline analog active against multidrug resistant cell lines. Proc 94th Am Assoc Cancer Res. (2nd ed) 44: R1617, 2003. e-Pub 2003.
173. Tarasova NI, Dyba M, Cochran C, Czerwinski G, Priebe W, Michejda CJ. Synthetic targeted anti-tumor agents: selection of effective toxic moieties. Proc 93rd Am Assoc Cancer Res 699, 2002. e-Pub 2002.
174. Priebe W, Evrony G, Fokt I, Lee S, Talpaz M, Donato NJ. WP744, A novel anthracycline highly active against STI-571 resistant tumors. 14th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics Eur J Cancer, 38 (Suppl 7), S126, 419, 2002. e-Pub 2002.
175. Liu H, Savaraj N, Priebe W, Lampidis T. Decreasing levels of external oxygen increases tumor cell sensitivity to 2-deoxy-D-Glucose: A strategy for solid tumor therapy. Proc 93rd Am Assoc Cancer Res 4711, 2002. e-Pub 2002.
176. Priebe W, Ashikawa K, Fokt I, Inge T, Aggarwal BB. Nuclear Factor-B Activation. A New Target for Drug Design?. 14th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics Eur J Cancer, 38 (Suppl 7), S105, 351, 2002. e-Pub 2002.
177. Priebe W, Evrony G, Fokt I, Talpaz M, Donato NJ. WP744, a novel anthracycline with enhanced apoptotic and anti-proliferate activity on STI-571 resistant leukemic cells: Design, synthesis, and evaluation. Proc 93rd Am Assoc Cancer Res 4197, 2002. e-Pub 2002.
178. Kirken RA, Nagy Z, Stepkowski SM, Kosinski S, Fokt I, Kahan BD, Priebe W. Targeting Jak3 with small molecules to inhibit T-cell proliferation. 14th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics Eur J Cancer, 38 (Suppl 7), S105, 353, 2002. e-Pub 2002.
179. Fokt I, Chaires JB, Priebe W. Synthesis of WP 901, an enantiomer of doxorubicin, and its Z-DNA selective binding. Proc The XXIst International Carbohydrate Symposium, Cairns, Australia, 2002. e-Pub 2002.
180. Priebe W, Fokt I, Wozniak K, Dominiak PM, Pastuch G. Synthesis of macrolides from functionalized glycals. Proc Am Chem Soc Meet: CARB-42, Boston, MA, 2002. e-Pub 2002.
181. Lampidis T, Liu HP, Savaraj N, Priebe W. Hypoxia hypersensitizes the slow-growing cells of solid tumors to glycolytic inhibitors. 14th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer Therapeutics, Eur Cancer, 38 (Suppl 7), S94, 308, 2002. e-Pub 2002.
182. Fokt I, Chaires J B, Priebe W. Synthesis of WP901, an enantiomer of doxorubicin, and its z-DNA selective binding. Proceedings: XXIst International Carbohydrate Symposium 2002, #545. e-Pub 2002.
183. Lampidis T, Priebe W. Exploiting glycolytic metabolism in hypoxic locations of solid tumors for therapeutic gain. Proc 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Miami, FL, 438, 2001. e-Pub 2001.
184. Pawloska J, Tarasiuk J, Priebe W, Wolf CR, Borowski E. The steric hindrance effect and the decrease of the basicity are the major factors essential for the reduction of stimulation of free radical formation by new sugar-modified derivatives of Daunorubicin and Doxorubicin. 8th International Symposium on Molecular Aspects of Chemotherapy under auspices of the International Society of Chemotherapy, European Federation for Medicinal Chemistry, and International Union Against Cancer, Gdansk, Poland, 16, 2001. e-Pub 2001.
185. Priebe W, Fokt I, Kowalczyk T, Krawczyk M, Grynkiewicz G, Szeja W. Glycals and Masked Glycals. Creation of structural diversity and biologically important libraries, Proc 221st Am Chem Soc Meet.: CARB- 77, San Diego, 2001. e-Pub 2001.
186. Liu H, Y-P H, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Proc 92nd Am Assoc Cancer Res 4368, 2001. e-Pub 2001.
187. Priebe W, Fokt I, Przewloka T, Woynarowski JM, Pratesi G, Supino R, Zunino F, Y-H L, Perez-Soler R. WP769, a novel orally active mechanistically altered doxorubicin analog. Proc 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 2000. e-Pub 2000.
188. Trevino AV, Woynarowska BA, Priebe W, Woynarowski JM. Enhanced topoisomerase II targeting by Annamycin and related 4-demethoxy anthracycline analogs. Proc 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 2000. e-Pub 2000.
189. Priebe W, Fokt I, Przewloka T, Grynkiewicz G, Chaires JB. A structure-based approach to DNA-binding anticancer agents. 7th Ibn Sina International Conference on Pure and Applied Heterocyclic Chemistry, Alexandria, Egypt Proc, 2000. e-Pub 2000.
190. Fokt I, Krawczyk M, Przewloka T, Grynkiewicz G, Priebe W. Synthetic approaches to clinically promising anthracyclines modified at the sugar moiety. Proc 20th International Carbohydrate Symposium, Hamburg, 2000. e-Pub 2000.
191. Priebe W. Antibiotics and Related Products (ICCA-7). 7th International Conference on Chem., Mierki, Poland, 2000. e-Pub 2000.
192. Priebe W. Masked Glycals, Glycals: Synthesis, conformation, and selective blocking. 13th International Conference on Organic Synthesis (ICOS-13) under IUPAC Sponsorship, Warsaw, Poland, 2000. e-Pub 2000.
193. Bouzyk E, Fuks L, Samochocka K, Lewandowski W, Fokt I, Przewloka T, Priebe W, Kruszewski M. Cytotoxicity and Induction of the DNA Crosslinks of Platinum and Palladium Complexes in Mouse Lymphoma Cell Lines. Proc 30th Annual Meeting of EEMS (European Environmental Mutagene Society) 35: 96, 2000. e-Pub 2000.
194. Bouzyk E, Fuks L, Samochocka K, Lewandowski W, Fokt I, Przewloka T, Priebe W, Kruszewski M. Cytotoxicity and induction of the DNA crosslinking of Platinum and Palladium complexes in mouse lymphoma cell lines. 30th Annual Meet EEMS (European Environmental Mutagene Society), Budapest, Hungary, 2000. e-Pub 2000.
195. Priebe W. WP769, a novel orally active doxorubicin analog. Proc 89th Am Assoc Cancer Res, San Francisco, 2000. e-Pub 2000.
196. Priebe W. Targeting DNA: A modular approach using structure-based design and combinatorial libraries. Proc Am Chem Soc Meet.: CARB, Washington, DC, 2000. e-Pub 2000.
197. Joseph, W G, Michael, J T, Katherine, B, Jeffrey, A H, Amy, C, Justin, F, Julia, A, Henry, C, Alain, B, Saloni, S, Christine, L, JangKeun, K, Jiwoon, P, Cem, M, Jonathan, F, Christopher, M, Yaron, B, Stephanie, R, Nusrat, J E, Brian, A, Josh, C, Mark, S, David, T, Timothy, B, Clifton, D, Mark, T H, Nathaniel, J M, Victoria, K B, Emily, A M, Sharon, T-B A, Elizabeth, J A, Wes, A S, Rebekah, J D, Gabrielle, A W, Kevin, J, Timmy, L, Deborah, M, Alessia, A, Soto Y, A, Arnold, O, Zimu, C, Joseph, D, Waldemar, P, Mark, R E, Sonja, M B, Kelsey M, J, Nidia, S T, Kevin, B C, Victoria, Z, Rob, M, Peter, G, Jonathan, C S, Pedro, M-V M, Simon, P, Christopher, E M, Syrkin E, W, Deanne, T, Robert, E S, Afshin, B, Douglas, C W, Stephen, B B. Lethal COVID-19 Associates With RAAS-Induced Inflammation For Multiple Organ Damage Including Mediastinal Lymph Nodes. bioRxiv.
198. Priebe, Waldemar. From carbohydrate chemistry to biology to sugar-based drugs. Abstracts of Papers, 258th ACS National Meeting & Exposition.
199. Priebe W, Skora S, Fokt I, Zielinski R, Jayakumar A, Venugopal R. Preparation of pyridylethenylamides as caffeic acid analogs for the treatment and prevention of. CAPLUS.
200. WADOLOWSKA A, Priebe W, S Sartor, G Martinelli, I Zacheo, Miranda E, E Wasyl, C Abbate, J Halka, Simona S, C Papayannidis, B Machalinski, S Milczarek, JP Waymack, G Marconi, W Dempke. LIPOSOMAL ANNAMYCIN IN COMBINATION WITH CYTARABINE FOR TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) (MB-106 STUDY).

Book Chapters

1. Perez-Soler, R, Khokhar, AR, Priebe, W, Krakoff, IH. Liposomes in Drug Delivery. In: Use of liposomes as carriers of lipophilic antitumor agents. 1st. Routledge, 1-9, 2017.
2. Debinski W, Priebe W, Tatter S. Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy. In: Glioblastoma. Part I: Targeted Cytotoxic Therapy. Codon Publications, 2014.
3. Priebe W, Fokt I, Grynkiewicz G. Glycal Derivatives, Synthesis and Chemical Reactions. In: Glycosicence - Chemistry and Chemical Biology. Frasier-Reid, Tatsuta, Thiem (Eds.), 1-38, 2007.
4. Grynkiewicz G, Achmatowicz O, Fokt I, Priebe W, Ramza J, Szechner B, Szeja W. Synthesis of natural and modified anthracycline antibiotics from a common precursor: 3,4-di-O-acetyl-L-rhamnal. In: Wiadomosci Chemiczne, 535-560, 2002.
5. Priebe W, Grynkiewicz G. Formation of an Anomeric Carbon-carbon Double Bond in Monosaccharides. In: Glycoscience: Chemistry and Chemical Biology. Springer-Verlag, 2001.
6. Priebe W, Fokt I, Przewloka T, Chaires JB, Portugal J, Trent JO. Exploiting the Anthracycline Scaffold for Designing DNA-Targeting Agents. In: Methods in Enzymology, Drug-Nucleic Acid Interactions. Academic Press, 529-555, 2001.
7. Ishikawa T, Priebe W. A New Challenge In The Post-Genome Era: Transport Mechanism-Based Drug Design Strategy. In: Global Outsourc Rev, 52-58, 2000.
8. Priebe W, Perez-Soler R. Sugar-modified anthracyclines: a search for drugs able to overcome multidrug resistance. In: Carbohydrates in Drug Design. Marcel Dekker, Inc, 1997.
9. Lampidis TJ, Kolonias D, Savaraj N, Israel M, Priebe W. Selectivity and localization of anthracyclines in cardiac-muscle non-muscle cells relevance to multidrug resistance. In: Analytical Use of Fluorescent Probes in Oncology. Plenum Press, 1996.
10. Perez-Soler R, Sugarman S, Zou Y, Priebe W. The use of drug carriers to ameliorate the therapeutic index of anthracycline antibiotics. In: Anthracycline Antibiotics. Novel Analogues, Methods of Delivery, and Mechanisms of Action. American Chemical Society, 300-319, 1995.
11. Priebe W, Skibicki, P, Varela O, Neamati N, Sznaidman M, Dziewiszek K, Grynkiewicz G, Horton D, Van NT, Zou Y, Y-H L, Perez-Soler R. Non-cross-resistant anthracyclines with reduced basicity and increased stability of the glycosidic bond. In: Anthracycline Antibiotics. Novel Analogues, Methods of Delivery, and Mechanisms of Action. American Chemical Society, 14-46, 1995.
12. Perez-Soler R, Khokhar AR, Priebe W, Sugarman S, Krakoff IH. Development of new lipophilic anticancer agents entrapped in liposomes. In: Drug Targeting and Delivery. Harwood Academic Publishers, 1-9, 1993.
13. Horton D, Priebe W. Glycon- and C-14 modified, antitumor doxorubicin analogs. In: Anthracycline Antibiotics. Academic Press, Inc, 197-224, 1982.

Books (edited and written)

1. Priebe W. Anthracycline Antibiotics. American Chemical Society, 1995.